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ABSTRACT 
Interleukin-(IL)-9 is a pleiotropic cytokine secreted by activated Th2 cells. 
Interleukin-9 and the a-chain of the IL-9 receptor (IL-9Ra) have been shown to affect the 
differentiation pathway of various cell types including human T cells, eosinophils, and 
mast cells, all key players in allergie inflammation. However, there is little information 
regarding the differentiation effect of IL-9 on B cells. Specifically, there are no reports 
describing the expression of the IL-9Ra on human B lymphocytes. To gain a better 
understanding of the effect of IL-9 on human B lymphocytes and its role in the B-Th 
immune synapse in the germinal center, we sought to determine the expression of the IL-
9Ra on human tonsillar B cells. This allows us to study the expression of the IL-9Ra on B 
cells at different stages of their antigen-driven maturation, in the context of B-T cell 
interactions. Human tonsillar B cells were fractionated, using a discontinuous percoll 
density gradient, into three populations representing different stages of B lymphocyte 
maturation: low density (LD) (recovered in the 30-50% Percoll fraction), which represents 
follicular mantle (FM) B cells and germinal center (GC) B cells, medium density (MD) 
(50-60%), which are primarily centroblasts and centrocytes, and high density (HD) (>60%) 
or more mature B cells. We have determined the expression of the IL-9Ra chain by 
immunocytochemistry, FACS analysis and immunohistochemistry. Immunocytochemistry 
was performed on freshly isolated purified human tonsillar B cells using a monoclonal 
antibody to the alpha chain of the IL-9R. This clearly demonstrated the presence of the IL-
9Ra prote in on tonsillar B cells. Using F ACS analysis, unfractionated as well as 
fractionated B cells showed positive immunoreactivity. However, IL-9Ra expression was 
predominantly higher in the LD fraction of the B cells (39%), as compared to the MD 
(22%), and HD fractions (16%). These findings prompted us to further investigate the 
precise localization of the IL-9Ra positive B cells within the germinal centers. For this 
purpose, immunohistochemistry was performed on sections ofhuman tonsils. Using double 
staining with anti-IL-9Ra and anti-CD20 (Alkaline Phosphatase anti-Alkaline Phosphatase 
APAAP) as well as with anti-IL-9Ra and anti-CD19 (immunofluorescence), we found that 
CD20+/CD19+ B cells within the secondary lymphoid follicles, and especially cells on the 
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edge of these follicles, displayed IL-9Ra. Furthermore, analysis of CD38 and IgD 
expression on IL-9Ra positive ce Ils by three color flow cytometry showed that IL-9Ra was 
expressed on FM B cells (CD38-IgD+) and GC ceIls (CD38+IgD+). Upregulation of 
phosphotyrosine levels in LD cells stimulated with IL-9 as well as signal transducers and 
activators of transcription (STATs) phosphorylation was detected by immunoblotting and 
flow cytometry respectively. The results show a specific upregulation of STAT-5 and 
STAT3 phosphorylation in LD cells and not in total B ceIls, MD or HD cells. In order to 
better define the effect of IL-9 on follicular B cells, we hypothesized that IL-9 played a role 
in the B-Th immune synapse in GC by promoting germinal center isotype switching, and 
affecting IgE production consequently. In order to directly assess the effect of IL-9 on IgE 
production, LD cells, which are germinal center cells expressing the highest level of IL-
9Ra in our analysis, were stimulated with an antibody to CD40 and IL-9 in the presence or 
absence of IL-4 and IgE production was measured by ELISA. Although IL-9 was unable to 
induce IgE secretion by itself, it potentiated IgE production mediated by IL-4. This 
suggests a synergistic role for IL-9 with IL-4 in modulating IgE production and B cell 
differentiation. This was accompanied by an upregulation of IL-9R and CD27 expression 
on LD ceIls throughout the culture period specificaIly following CD40 and IL-4 
stimulation. No further increase in expression levels was observed in the presence ofIL-9. 
Furthermore, CD27 upregulation occurs almost entirely on IL-9R positive cells, pointing to 
an important role for IL-9 downstream of CD40 and IL-4 signaling in B ceIl differentiation. 
The observed increase in IgE production was not due to an increase in cell number as IL-9 
was not able to potentiate IgM-activated LD B cell proliferation, nor anti-CD40-activated 
LD B cell proliferation. Moreover, no synergistic effect for IL-9 on IL-4 induced LD B cell 
proliferation was observed. However, IL-9 protected LD B cells from Fas-induced 
apoptosis, suggesting an important role for IL-9 in B cell survival. In summary, IL-9 
synergizes with IL-4 to augment IgE production in LD cells, it does so by enhancing cell 
survival rather than by increasing cell number. 
These data show for the first time that a functional IL-9Ra chain is expressed on 
human foIlicular germinal center B cells. Taken together, our studies establish a new 
VI 
understanding for the role of IL-9, a cytokine linked to increased susceptibility to allergy 
and asthma, in B cell maturation and IgE production. 
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SOMMAIRE 
L'Interleukin-9 (IL-9) est une cytokine pléiotropique sécrétée par les lymphocytes 
T de type 2 (Th2). L'IL-9 et la chaîne a. de son récepteur (IL-9Ra.) sont impliquées dans 
la différentiation de divers types cellulaires incluant les lymphocytes T humains, les 
éosinophiles, les cellules 'mast', tous jouant un rôle dans l'allergie inflammatoire. 
Cependant, il existe peu d'information concernant l'effet de l'IL-9 sur la différentiation 
des lymphocytes B. Dans le but de mieux caractériser cet effet, nous avons déterminé 
l'expression du récepteur de l'IL-9 (IL-9Ra.) sur les cellules B humaines des amygdales. 
Ce choix nous permet d'étudier l'expression de l'IL-9Ra. sur les lymphocytes B à 
différentes étapes de leur maturation en périphérie suite à l'exposition à un antigène dans 
le contexte des interactions des lymphocytes B et T. Les lymphocytes B purifiés des 
amygdales ont été fractionné en utilisant un gradient sur Percoll (discontinuous percoll 
density gradient) en trois populations représentant différents stades de maturation des 
lymphocytes B: les lymphocytes B de faible densité (retrouvés dans la fraction de percoll 
30-50%), représentant les cellules B germinales ou les cellules B 'LD', les lymphocytes 
B de densité moyenne (50-60%), qui sont principalement constitués de centroblastes et de 
centrocytes ou 'MD', et les lymphocytes B de haute densité récupérés à> 60% constitués 
de cellules matures inactives en majorité (RD). Nous avons déterminé l'expression de 
l'IL-9Ra. par immunocytochimie, FACS et immunohistochimie. L'immunocytochimie 
sur des lymphocytes B d'amygdales fraîchement isolées et purifiées a été faite à l'aide 
d'un anticorps monoclonal dirigé contre la chaîne alpha du récepteur de l'IL-9. Ceci 
démontre clairement la présence de la protéine IL-9Ra. sur les lymphocytes B des 
amygdales. L'analyse par FACS de cellules B fractionnées ou non sur un gradient de 
Percoll a montré la présence de l'IL-9Ra. sur les cellules B. Nos résultats montrent une 
expression nettement élevée chez les cellules B germinales (39%), comparées aux 
cellules MD (22%), et les cellules RD (16%). Ces résultats nous ont incité à rechercher la 
localisation précise de l'IL-9Ra. dans les centres germinaux. Pour réaliser cet objectif, 
nous avons effectué un double marquage de sections d'amygdales, en utilisant un 
anticorps dirigé contre l'IL-9Ra. et un autre contre CD20 (APAAP) ainsi qu'un anti-IL-
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9Ra et anti-CDl9 (immunofluorescence). Nous avons montré que les cellules B 
CD20+/CD 19+ dans les follicules lymphoïdes secondaires, et particulièrement les 
cellules aux bords de ces follicules, exprimaient l'IL-9Ra. De plus, l'analyse par 
cytométrie de flux de l'expression de CD38 et IgD sur les cellules positives pour l'IL-
9Ra a montré que l'IL-9Ra est exprimé sur les cellules B folliculaires ou 'FM' B cells 
(CD38-IgD+) et les cellules B germinales GC (CD38+IgD+). L'augmentation en 
expression de la phosphotyrosine chez les cellules de faible densité (LD) ainsi que la 
phosphorylation des molécules STATs ont été montrées par la cytométrie de flux et par 
western blot. Les résultats montrent une augmentation de la phosphorylation de ST AT5 
et ST A T3 uniquement chez les cellules LD et non chez les cellules B non fractionnées, 
les cellules MD ou HD. Afin de vérifier l'hypothèse selon laquelle l'IL-9 affecte les 
cellules B folliculaires en induisant un 'germinal center isotype switching', et par 
conséquent en influant la production d'anticorps IgE, nous avons décidé de vérifier 
directement l'effet de l'IL-9 sur la production IgE: les cellules LD, exprimant le plus 
haut niveau d'IL-9Ra selon notre analyse, ont été stimulées avec un anticorps dirigé 
contre CD40 en présence ou en absence d'IL-4 et la production d'IgE a été mesurée par 
ELISA. Bien que l'IL-9 était insuffisante pour induire la sécrétion d'IgE, elle a augmenté 
la production d'IgE médiée par l'IL-4. Ce qui suggère l'existence d'une synergie entre 
l'IL-9 et l'IL-4 dans la modulation de la production d'IgE et la différentiation des 
lymphocytes B. De plus, nous avons noté une augmentation de l'expression de l'IL-9Ra 
et de CD27 sur les cellules LD stimulées spécifiquement en présence de l'anti-CD40 et 
l'IL-4 au cours de la culture cellulaire. Il n'y a pas eu d'augmentation en présence de 
l'IL-9. L'uprégulation de CD27 a lieu presque spécifiquement sur les cellules IL-9R+, 
suggérant un rôle important de l'IL-9 suivant la signalisation par CD40 et IL-4 dans la 
différentiation des lymphocytes B. L'augmentation de la production d'IgE n'était pas due 
à un nombre de cellules accru car l'IL-9 n'a pas augmenté la prolifération des cellules LD 
stimulées par IgM ou CD40. De plus, l'IL-9, associée à l'IL-4, n'a pas augmenté la 
prolifération cellulaire. Par contre, l'IL-9 a un effet protecteur contre l'apoptose induite 
par Fas, impliquant l'IL-9 dans la survie des cellules B. En résumé, l'IL-9 synergise avec 
l'IL-4 afin d'augmenter la production d'IgE chez les lymphocytes B LD, et ce en 
affectant la survie cellulaire plutôt que la prolifération. 
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Cette étude démontre, pour la première fois, l'expression d'un récepteur fonctionnel 
de l'IL-9 sur les cellules B folliculaires germinales humaines. En effet, nos résultats 
établissent un nouveau rôle pour l'IL-9, une cytokine liée à la susceptibilité à l'allergie et 
l'asthme, dans la maturation des lymphocytes B et la production d'IgE dans le contexte 
de la synapse entre les cellules B et T dans les follicules secondaires. 
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CHAPTER 1. INTRODUCTION 
1 
1. The Basis of the Immuue Response to Infection 
Our immune system' s main function is to combat foreign living microorganisms 
that may invade our bodies. The response operates on two levels: an automatic unrefined 
process which cannot be further improved through leaming known as 'the innate defense 
mechanism', and a memory based evolving response that acts in conjunction with the 
innate response to provide vigorous protection efficient in combating extracellular and 
intracellular infections known as 'the specific acquired response'. The key factors 
contributing to the initiation of these two types of immune responses are the pathogens, 
which when introduced to the host are recognized and eliminated. Based on their 
differential ability to detect the presence of infectious agents and dispose of the invaders, 
the two distinct immune-recognition systems have been broadly categorized as 'innate' 
and 'adaptive'. 
I.A. Innate Immunity 
From plants to humans, multicellular organisms are endowed with an inbom set of 
mechanisms that ensures their survival upon encounter with pathogens (bacteria, fungi, 
viruses, etc .. ). This is referred to as innate immunity. It is the initial response to infection 
that occurs immediately or within several hours after exposure to an antigen to eliminate 
microbes and prevent infection. It is mediated by antigen-nonspecific defense 
mechanisms. This phase is essential for the subsequent development of the adaptive 
immune response. As argued by Douglas T. Fearon of the University of Cambridge, U.K., 
and Richard M. Locksley of the University of Califomia, San Francisco l "Mammalian 
innate immunity is not merely a vestige of ancient antimicrobial systems that have been 
made redundant by the evolution of acquired immunity. Rather, it dictates the conduct of 
the acquired immune response." 
Understandably, the invading pathogens are responded to by the acquired immune 
system which cooperates with the first line of defense offered by the innate response to 
succeed in curtailing the spread of infection. 
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I.B Adaptive Immunity 
The most distinguishing elements of this phase of the immune response are 
antigen specificity and memory. Acquired immunity has nearly infinite adaptability in 
responding to new pathogens: the T and B lymphocytes of the acquired immune response 
can rearrange the elements of their immunoglobulin and T-cell receptor genes to create 
different clones with distinct antigen receptors. B cells are the mediators of humoral 
immunity, they can generate up to 1014 different antibody with different specificities and 
different classes 2. Once acquired immunity has dealt with a pathogen, sorne antigen-
specific clones remain as memory cells that mediate a more rapid response the next time 
the pathogen is encountered. 
I.B.1. Role of T CeUs in Antigen Recognition and Initiation of the 
Immune Response 
Antigen-specific T cells originate from thymus with receptors able to recognize 
peptides bound to major histocompatibility complex class 1 or class II molecules (MHC 1 
and MHC II). Detection of a specifie peptide-MHC (pMHC) complex expressed on 
APCs at a density of only 0.1-1 molecules/~m2 is sufficient to induce robust T cell 
activation 3. These thymus-derived lymphocytes circulate in the blood and lymphoid 
organs such as the lymph nodes, spleen, and the Peyer's patches of the intestinal mucosa 
until encounter with antigen-presenting cells (APCs) bearing specific MHC-peptide 
complexes. It is their peptide specificity that distinguishes these receptors, and their 
ability to interact with different affinities to the same peptide hence translating small 
quantitative differences in ligand binding into qualitatively different signaIs 3. Dendritic 
cells are the most competent of aIl APCs in triggering T cell responses: they express a 
high level ofMHC molecules along with a variety of 'accessory molecules' that help DCs 
to be more efficient in stimulating T cells 4. However, a recent study using BM chimeras 
in mice allowing the depletion of MHCII molecules specifically in B cells has shown that 
cognate interaction through MHC-II on B cells was essential for both clonaI expansion 
and differentiation of CD4 T cells. Hence, in vivo B cells were shown to provide essential 
3 
additional Ag presentation capacity to that provided initially by DC 5. Two alternative 
paths may be initiated following ligand binding on T cells and APCs, one involving 
CD8+ T cell activation for the cells expressing antigen receptor of the same specificity, 
the other involving CD4+ T helper cell activation of other cell types, namely B cells 
(Figure 1). The induction of B cell proliferation and differentiation contributes to the 
establishment of humoral immunity. 
What are the requirements for B cell activation, and what is the outcome of these 
interactions? 
I.B.2. Antigen recognition by B cell receptors 
The first comprehensive theory that addressed the function and production of 
antibodies was proposed by Ehrlich in his si de-chain theory (Ehrlich P. et al. The 
Croonian Lecture. On immunity with special reference to cel/ life. Proc Soc Lond Biol 
1900; 66:424-448). Although the amplitude of the repertoire of antigen specificity was 
not weIl appreciated, he postulated that naturally occurring antibodies described as side-
chains acted as receptors on the cell surface. Vpon antigen recognition and binding, these 
molecules were shed from the cell surface, and the cell compensated for this loss by 
producing and releasing more antibodies into the circulation. 
It is not until more than fifty years later that the clonaI selection theory (CST) was 
advanced by F. M., Burnet clarifying the nature ofthe cell producing antibodies as weIl as 
its specificity (Burnet F. M The Clonai Selection Theory of Acquired Immunity. 
Cambridge: Cambridge University Press, 1959). Burnet proposed that a specifie immune 
response can be explained in terms of the selection of a specific clone by a specifie 
antigen. One B cel/: one antibody supported the implications ofthis theory 6. 
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Figure 1: Band T cell activation. 
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Communication of the innate immune response with the effector cells of the adaptive 
immune response by synapse formation. 
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The ability to distinguish self from non-self and to initiate a specific immune 
reaction following recognition of non-self or foreign antigens constitutes the basis of this 
theory. This model has been modified over the years to include the need for a second 
signal for Band T cells to trigger a productive immune response and escape cell death 7,8. 
In 1989, Janeway proposes the infectious non-selfmodel (INS) whereby APes do not co-
stimulate T cells unless activated via PRRs (receptors for evolutionarily distant infectious 
non-self 9. The self non-self model has been challenged by Matzinger, P. and colleagues 
in her danger the ory proclaiming that the immune system' s decision to react to a stimulus 
is determined by the 'danger' it poses to the host rather than its compliance with the self 
non-self model. Within this mode l, alarm signais released by stressed or injured cells are 
what triggers an immune response and not the identification of a 'foreign' antigen 10,11. 
To date, scientists are still studying the different regulatory mechanisms that induce and 
modulate antibody production. 
The expression of a functional BeR is a prerequisite for the initiation of an 
immune response leading to antibody production. B cells undergo an antigen-independent 
maturation process in the bone marrow with different checkpoints involving factors and 
signais from outside and inside of a B cell precursor that predict survival, growth and 
maturation of B lymphoid progenitors before the appearance of mature Ig receptors 12. 
This developmental pathway depends on several transcription factors, including early B-
cell factor, PU. 1, E2A and paired box protein 5 (PAX5) 13. Studies of primary immune 
deficiencies in humans, transgenic and gene inactivation models in mice, have allowed 
the characterization of progressive developmental checkpoints leading to the expression 
of a pre-BeR 14. A model delineating these different stages in humans and mice is 
depicted in figure 2 15-18. The first checkpoint in B cell development relies on pre-BeR 
expression and signaling at the pro-B/pre-B transitional stage both in human and mouse. 
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Figure 2: Human and mouse BM B cell development pathways. 
Blockages in human and mouse B cell differentiation pathways in the bone marrow as a 
result of deficÏencÏes in certain signaling proteins. Complete and incomplete blockages 
are indicated by full and dashed arrows, respectively. (depicted from Espeli, M et al. 
(14)) 
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The pre-BCR, transiently expressed by developing precursor B ceIls, comprises 
the Ig J.1H chain, surrogate light (SL) chains VpreB and Â.5, as weIl as the signal-
transducing heterodimer Ig alIg p. Signaling through the pre-BCR regulates allelic 
exclusion at the Ig H locus, stimulates cell proliferation, and induces differentiation to 
small post-mitotic pre-B cells that further undergo the rearrangement of the Ig L chain 
genes 19. Immature B cells subsequently express a complete IgM molecule on their 
surface. The second checkpoint is successfully passed in the presence of surface IgM, this 
allows negative selection to occur. B lymphocytes leave the bone marrow at the 
transitional B cell stage and complete their final development into mature B cells in the 
periphery 20. Selccted B cells exiting the BM, undergo a progressive maturation from 
transitional B cells (Tl) Tl B cells to T2 B cells to fully mature B cells. Different levels 
of surface markers distinguish these cellular subsets: Tl cells are IgMhigh IgD- CD21-
CD2r, whereas T2 B cells are IgMhigh IgD+ CD21+ and CD23+ 21-23. Immune 
Competence is acquired as B cells progress from Tl to T2 with a second round of 
negative selection to fully mature. The majority of B cells will recirculate in the spleen 
and other lymphoid organs until encountering their cognate antigen and undergoing 
antigen-dependent maturation in the periphery 24. 
Initiation of the antibody response depends primarily on antigenic stimulation of 
the B cell receptor (BCR). SignaIs transmitted by the B cell Ag-receptor (BCR) influence 
not only cellular selection, maturation, and survival, but are imperative in generating the 
ultimate effector function of B cells, i.e. antibody production. Vpon BCR triggering, a 
series of intracellular events take place leading to cell proliferation and differentiation 
25,26. The BCR also plays a role in antigen uptake, which, following intracellular 
processing, leads to presentation of antigen-derived peptides on MHC II molecules to T 
cells 27,28. A BCR may interact with either soluble or membrane-associated antigens, 
however, membrane-bound antigens are most effective in promoting B cell activation 29. 
As an example of the affinity of such interactions, soluble self-antigens of high-affinity 
induce anergy 30, whereas low-affinity membrane self-antigens lead to B cell deletion 31. 
Other forms of soluble antigen bound to Fc portion of antibodies or complement forming 
an immune complex (lC) that is in a membrane-anchored form can induce the BCR, 
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constituting the most common form of antigen encountered by B cells 32. Oendritic cells 
can present antigen to B cells 33. Furthermore, in germinal centers, follicular dendritic 
cells have been shown to retain IC for presentation to B cells 34. Presentation of intact 
antigen as a transmembrane prote in triggers formation of a BCR-dependent 
immunological synapse (B synapse). The B cell synapse extracts intact antigen from the 
APC, pracesses it to generate peptide-MHC complexes for B-Th synapse formation 35. 
Neuberger and colleagues have shown that immune complexes captured on FcR+ cells 
can be presented to form a B synapse (Figure 3). The presentation of intact antigens as 
immune complexes on FOCs is thought to be important for the affinity maturation of 
antibodies 36. As antigenic stimulation plays a raIe in OC activation and maturation, it is 
interesting to view the B-OC synapse and the potential role of cytokines in this 
interaction. Identification of cytokine receptors on DCs may elucidate their 
immunoregulation and characterize their role in B cell responses. 
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B cell 
Figure 3: B cells and the APC immune synapse 
In a tirst stage antigens or immune complexes captured by DCs are presented to B 
lymphocytes in the context of the B synapse. Consequently the B cell acts as a bridge 
relaying the extracted antigen and presenting it to helper T lymphocytes (T synapse). In 
the B synapse, molecules that negatively regulate the BCR signalosome are excluded 
from the synapsis area. (LN, lymph node; LFA-l, lymphocyte function-associated 
antigen 1). (depictedfrom Dustin, M et al. (36) 
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II. The Humoral Immune Response: 
The adaptive humoral immune response develops slowly, requiring at least one 
week and resulting in the production of monospecific, high-affinity antibodies, tirst of 
IgM and later, after class switching, ofIgG, IgA and/or IgE type 37. 
II.A. B-cell Activation by helper T cells 
The dual role that B cells play in adaptive immunity involves antigen presentation 
and development of effector mechanisms following antigen exposure. Encounter of a 
naïve B cell with antigen prepares it to activate T cells and receive T cell-derived help 
signaIs. How the B cell prepares for such collaboration involves different stages that 
progress temporally, ultimately leading to the expression of cell-surface molecules 
important for productive interaction with T cells. 
II.A.1.B-T cell interaction and the immunological synapses 
The main form of communication between activated B cells and helper T cell 
clones is the immune synapse which impacts cell-fate decision in T-dependent B-cell 
responses. Figure 4 depicts the three synapses that occur within days of antigenic 
exposure over the course of the primary immune response within the secondary lymphoid 
foUicles as described by McHeyzer-Williams, M. G. et al. 38. Synapse 1 interactions occur 
concomitantly between activated Des and naïve antigen-specific T cells 35, as weIl as 
antigen-primed Des and naïve circulating B cells brought to T cell areas in the spleen or 
lymph nodes. This initial step allows maturation of the antigen presenting B cell by 
providing an efficient means for antigen and BeR internalization 38, and activation of the 
T cell to allow the provision ofhelp to activated B cells. 
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Figure 4: Immunological Synapses 
Helper-T -cell regulated B-cell differentiation. Phase 1 begins at the site of infection with 
activation and emigration of Des to the T-cell zones of the lymph nodes. Initiation of 
immune synapse 1 (Synapse 1) oceurs at this stage allowing the activated Des to contact 
and trigger naïve Th cells expressing specific T -cell receptor (TeR). Studies have 
indicated that B cells can initiate an immune synapse with an activated antigen-bearing 
De as weil. Phase II oceurs following clonaI expansion, with cognate contact between 
antigen-specific B cells and antigen-activated Th cells within immune synapse II 
(Synapse II). Synapse II drives B-cell differentiation to either short-lived plasma-cell 
production, which progresses in the T -cell areas or movement into the follicular areas and 
the formation of secondary lymphoid follicles. Phase III begins with the Ge reaction and 
polarization of secondary follicles into light-zone and dark-zone regions. Mechanisms of 
clonaI expansion, SHM of the BeR, and antigen-specific selection for high affinity 
variants mark this phase leading to export of memory B cells. These memory B cells can 
either differentiate into long-lived plasma cells, or remain as non-secreting precursors for 
antigen recall. Synapse III interactions involve antigen-specific Ge Th cells and Ge B 
cells and are proposed to play a critical regulatory role in these late-stage B-cell 
developmental decisions. (depictedfrom McHeyzer-Williams, M G. et al. 38) 
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Immune synapse II forms upon presentation of antigenic peptides in the context of 
MHC II proteins by antigen-specific B cells to cognate T ceIls, thus leading to B cell 
activation creating the first stage of antigen dependent B cell differentiation. Activated B 
cells either proliferate and terminally differentiate to antibody-secreting cells in the T -ce Il 
zone of the lymphoid organ, or after initial activation may migrate to the follicular area 
and initiate the formation of a Ge. The role of CD40 and its ligand CDl54 is crucial in 
modulating the outcome of this interaction and constitutes a prerequisite for GC 
development. It is in the GC that B cells activate somatic hypermutation of their 
immunoglobulin genes and then undergo a stringent selection for high affinity binding to 
antigen, resulting in the production of memory B cells and plasma cells secreting 
antibodies of high affinity. 
II.B. The Germinal Center Response 
Following activation, Ig~ B cells migrate to the secondary lymphoid organs 
where they undergo antigen-driven maturation (Figure 5). Germinal centers (GCs) 
originate from a few founder B cells that undergo rapid clonaI expansion 39,40. To 
diversify the antibody repertoire, these proliferating B cells (centroblasts) undergo 
somatic hypermutation (SHM) of their immunoglobulin variable region genes within the 
GC dark zones 41-44 and give rise to centrocytes that are not in cell cycle and fill the light 
zone. SHM, in which point mutations are introduced into the variable region of 
immunoglobulin heavy and light chains, enables the selection of B cells that generate 
antibodies of higher affinity for antigen 45,46. Selection based on the highest antigenic 
affinity and specificity occurs in the GC light zones by interaction of B cells with 
follicular dendritic cells (FDC) and GC T cells 47,48. The light zone contains a ri ch 
network of follicular dendritic cells (FDC) that have the capacity to take up antigen and 
ho Id it on their surface. Centrocytes appear to be selected by their ability to interact with 
antigen he Id on FDC 49. There is a high death rate among centrocytes in vivo, and when 
these cells are isolated in vitro, they undergo apoptosis within hours of culture. Long-term 
survival is achieved by signaling through their surface CD40. Both BCR and CD40 
pathways, alone or together, contribute to B cell proliferation and differentiation 50. B 
14 
cells subsequently differentiate to memory or plasma B lymphocytes 51. This maturation 
process in the GC can be viewed as phases of B cell proliferation and mutation, followed 
by selective survival. Genetic analyses have shown that Activation Induced Cytidine 
Deaminase (AICD) is essential for both CSR and SHM 52,53. It is by taking this joumey 
within immunized peripheral lymphoid tissues, and via a progressive acquisition and loss 
of different surface markers, that the B cell matures and acquires its effector function. 
What are the different phenotypes that a maturing B cell displays throughout the GC 
reaction, and what molecules and/or cytokines orchestrate their expression? 
15 
Plasma cells 
CD38- I;!?: 
16 
Figure 5: The Germinal Center Reaction 
Fonicular mantle B cens (CD3S-IgD+) are antigen-activated B cens that enter secondary 
follicules from periphery. Depending on their BCR affinities, a few are selected as 
founder GC cens (CD3S+IgD+), which undergo somatic hypermutation of their IgV 
region genes and proliferate in the dark zone (DZ) of the follicle as centroblasts. 
Centrocytes are selected based on their affinity to antigen expressed by FDCs or T cens. 
Centrocytes with low affinity to antigen on FDC or T cens die by apoptosis. Centrocytes 
present peptides from FDC-derived Ag to local T cens. Selected Centrocytes may class 
switch their immunoglobulin genes and differentiate into plasma cens, memory B cens or 
go through receptor editing to enhance their affinity to antigen. 
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The definition of distinct subsets of B ceIls derived from human tonsillar 
lymphoid tissue representing different stages of peripheral B-ceIl development was done 
by Liu, YJ, Arpin, C. et al. 43. Most other studies addressed memory development in 
humans in PBL which do not reflect the entire developmental process as is the case with 
tonsillar B ceIls. As human tonsils receive repeated antigen stimulation and may display 
aIl stages ofperipheral B ceIl development 54. Based on the work of Liu, YJ et al. B ceIls 
can be sorted into four subsets established using anti-IgO and anti-C038 double 
immunofluorescence staining (Figure 6). Additional markers can be used to further 
subdivide each subset such as C023 which separates naïve B ceIls into an IgO+C038-
C023- subset (Bml), and an IgO+C038T023+ activated subset (Bm2). In tum, (GC) 
IgD+C038+ ceIls can be separated into C077+ centroblasts (Bm3) and CD7T centrocytes 
(Bm4). A model representing localization of these subsets within GCs is depicted in 
figure 6. 
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Figure 6. Phenotypic and functional characterization of human B-cell subsets 
The five main developmental stages of differentiation of human peripheral B cell 
maturation in secondary lymphoid follicles as proposed by Liu et al developmental model 
43 
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The earliest GC B cells (GC founder cells) are Ig~IgD+CD38+ B cells; they are 
characterized by the expression of naïve B cell markers IgM and IgD, and GC markers 
CDIO, CD38 and CD7l. They also express Fas/CD95 with little or no bcl-2 with a 
propensity to spontaneous apoptosis during culture 55. The availability of apoptosis 
program early in GC formation ensures that only GC founder cells with the highest 
affinity for antigen, bearing unmutated antigen receptors, will be selected to undergo 
somatic mutation. Once entered in the GC dark zones these cells have to mutate and 
improve the affinity of their antigen receptors rapidly to escape cell death. Selection and 
somatic mutation occur concomitantly 56. 
Analysis of centrocytes in the light zones of human tonsils showed a selective 
detection of sterile transcripts, a marker for the initiation of isotype switch 57-59. As 
centrocytes are localized in the vicinity ofT cell help in that area, the detection of isotype 
switching fits with the reported role of CD40-ligand 60,61 and secreted IL-4 and IL-IO 62 in 
modulating isotype switching. Other unidentified T cell expressed molecules and/or 
cytokines may also play a role as switching factors and affect the differentiation pathway 
of B cells at this stage. 
ln vitro studies have attempted to recreate the in vivo situation where high affinity 
GC B cells have picked up antigen from follicular dendritic cells 63 and present it to 
CD40-ligand-expressing GC T ce Ils 60,61. Upon culture of GC B cells with CD40-ligand-
transfected L cells with IL-2 and IL-I 0 for three days, cells enter a proliferative phase and 
grow exponentially 64. Two outcomes for GC B cells are obtained in vitro depending on 
the presence of CD40L for long term culture or its absence, memory or plasma cell 
differentiation. Findings from different culture systems confirmed the inhibitory effect of 
CD40L on B-cell differentiation to the plasma cell pathway 51,65,66. The presence of 
cytokines allows the differentiation ofB cells to secrete immunoglobulins. 
II. C. Master Regulators of B cell differentiation 
These successive differentiation steps are controlled by transcriptional regulators. 
Among these factors, PRDMI the human homologue of Blimp-l, is a transcription 
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repressor acting to facilitate the germinal center response by promoting plasma cell 
differentiation 53. This is accompli shed by repressing the expression of other genes: 
cMYC which affects B-cell proliferation and cell cycle progression 67, Pax 5 with its role 
in B cell maturation and suppression of the secretory pathway 68, and BCL6 which arrests 
further development ofGC cells 69. Another factor involved in plasma cell differentiation 
is XBP-l 70, a target of Pax 5. Initiation of the germinal center response following CD40 
stimulation depends on NF-KR 71, and induction of activation-induced cytidine deaminase 
(AICDA) which is required for SHM and CSR 52. BCL6 is also required for the formation 
of GC, where it acts in a B cell-autonomous manner to repress genes involved in the 
control of lymphocyte activation and cell cycle progression, allowing rapid cell 
proliferation 69. BCL6 also arrests further development by acting in concert with PAX5 
(BSAP) to repress genes involved in plasmacytic differentiation 72. These genes play an 
important regulatory role for B cell maturation, any defect caused by chromosomal 
translocation is associated with disease leading to a variety of human non-Hodgkin's 
lymphomas 73. 
II.D. Contact-mediated signais 
The regulation of B-cell effector functions is mediated by the interaction of 
several receptor-ligand pairs. These contact-mediated signaIs are received from an 
activated T ceIl, and contribute to the development of affinity maturation and the humoral 
memory response of B cells (Table 1). The first receptor implicated in transduction of 
contact-dependent B cell activation signaIs to be described was MHC class II. In 1987, it 
was reported that engagement of MHC class II on naïve murine B cells induces the 
activation of Protein Kinase C molecules, elevation of intracellular cAMP, and 
occasionally apoptosis 74-76. More recently, it was shown that triggering of MHC II with 
antigen in the presence of IL-4 leads to its association with immunoglobulin (Ig)-a/Ig-J3 
(CD79a/CD79b) heterodimers, which function as signal transducers upon MHC class II 
aggregation by the T cell receptor (TCR) 77. 
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Contact-mediated interaction of Band T cells involves different B cell Transmembrane receptors and T cellligands. 
In addition to the vital interaction of Band T cells through MHC II, both Band T 
lymphocytes express various transmembrane adhesion molecules, whose surface 
expression is increased after activation signaIs. Both cell types express ICAM-l (CD54) 
and LFA-l (CD 11 a/CD 1 8), which bind to each other and can thus mediate both 
homotypic and heterotypic adhesion which may amplify activation signaIs delivered by 
one cell type to the other 78. It was shown that such signaIs can contribute to enhanced B 
cell antigen-presentation 79 and cooperate with CD40 mediated signaling 80. Moreover, 
other costimulatory molecules are crucial for the germinal center reaction, namely ICOS 
whose deficiency results in a severe reduction of class-switched B cells in human patients 
leading to a clinical phenotype described as a common variable immunodeficiency 81. 
II.D.l. The Role of CD40 Stimulation in B Cell Maturation 
The most extensively studied B-cell surface molecule involved in the generation 
of T-dependent humoral responses following antigen challenge is the TNF-R family 
member CD40, which is constitutively expressed on mature B cells and, upon 
stimulation, recruits a family of adapter molecules called 'TNF-R-associated factors' 82 
TRAFs 1, 2, 3, 5, and 6, leading to activation of NF-KB, JNK, p38, and PI3K 78. The 
CD40 ligand (CD40L), CD154, is highly expressed primarily on the surface of activated 
T cells as a membrane-bound trimer, particularly following CD80/86-mediated CD28 
coreceptor signaling 83. Activation ofB cells through CD40 occurs only following antigen 
encounter of B cells which upregulates CD80/86 expression and receiving T cell help. 
The CD40/CD154 interaction constitutes a crucial step in T cell-dependent B cell 
activation and differentiation as evidenced by the pathology associated with its genetic 
alteration leading to abnormal CD40L expression in humans suffering from the X-linked 
hyper-IgM syndrome 84. This provides a molecular basis for immunoglobulin isotype 
switch defects observed in this immunodeficiency. The murine models of gene deficiency 
both in CDl54 85 and CD40 knock-out mice 86 demonstrate the important role of 
CD40/CD 154 interaction in the humoral response and germinal center formation. The 
biological outcome of CD40 engagement on B lymphocytes being proliferation, antibody 
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secretion, cytokine production, upregulation of different surface molecules involved in 
antigen presentation, isotype switching, development of germinal centers as weIl as a 
humoral memory response 87,88. Signaling through CD40 elicits a broad variety of 
immune and inflammatory responses 87,89, and is not restricted to B lymphocytes only but 
can also be triggered in dendritic ceIls, monocytes, epithelial ceIls, endothelial ceIls, and 
fibroblasts 89. Hence, abnormal CD40 signaling is associated with the pathogenesis of 
chronic inflammatory diseases such as auto immune diseases 90, neurodegenerative 
disorders 9\ graft-versus-host diseases 92, cardiovascular diseases 93, and cancer 94. 
In mice, the role of CD40/CD154 interaction in B lymphocyte activation, 
proliferation, and differentiation has been addressed using CD40/CD154 knockout mice 
85,86,95. The dysfunctional CD40 signaling revealed its essential role in isotype switching, 
somatic hypermutation, generation of memory B lymphocytes, and Ig production. Since 
disruption of the gene blocked the development of a memory response 96 by preventing 
the GC reaction to be initiated, direct evidence for the effect of CD40 on B cell memory 
development was sought from wild-type in vivo models, whereby neutralization of 
CD40L with anti-CD154 inhibited the secondary humoral response to T-dependent 
antigens 97, strongly confirming the essential role of CD40 in memory B lymphocyte 
responses in mice. 
In humans, patients suffering from the hyperlgM syndrome, presented deletions or 
mutations in the expression of CD40 98. This resulted in impaired B lymphocyte 
activation and Ig production. To determine the direct effect of CD40/CD154 interaction 
on human B cell memory development, studies in humans have been limited to in vitro 
systems. The impact of CD40 stimulation on B lymphocytes from peripheral blood or 
tonsils has been studied using different tools to stimulate CD40: cells transfected with 
CD154, anti-CD40 Abs, or soluble CD154 in the presence ofIL-4 99. 
The first system to be described for in vitro stimulation of B cells the 'CD40 
system' was developed by Banchereau, Rousset et al. 64, Tonsillar B cells were cultured 
with CD32-transfected fibroblasts coated with anti-CD40 mAb and IL-4. Analysis of IgD 
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expression showed no decrease for its expression on cycling naïve B cells, and these cells 
had very modest soluble Ig synthesis 100, suggesting that B lymphocytes were blocked in 
their differentiation. However, a switch to IgE was detected subsequent to the addition of 
soluble anti-CD40 and IL-4 to B cell cultures 101; other cytokines such as IL-IO enhanced 
IgG secretion 102, and stimulated B cell differentiation into morphologically typical 
plasma cells 103. Hence, these results showed that the differentiation block observed with 
IL-4 could be overcome by other cytokines. However, a group reported that using this 
'CD40 system' yielded differential outcomes whether a naive or a memory B cell was 
used independent of the cytokine added in the milieu (Figure 7A) 87. Only memory B 
cells were induced to secrete Ig, thus pointing to the impact of the maturation stage of the 
B cell at the time of interaction with T cells on the outcome i.e proliferation vs 
differentiation and Ig production 99. 
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Figure 7 A: Biological effects of CD40 activation on different stages of B cell 
development. 
CD40 activation mediates maturation of B cells from pre-B cells to naive B cells, 
germinal center (GC) B cells, or memory B cells. CD40 activation of memory B cells can 
lead to reentry into the germinal center and/or accelerated differentiation into Ig-
producing plasma cells (depictedfrom van kooten, C. et al. 8} 
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Figure 7B: Differentiai outcomes for CD40 activation depending on the maturation 
stage of B ceUs. 
Model of the interactions between CD40, surface Ig (sIg), and Fas signaling and the 
different effects depending on the maturation stage of B cells. (A) CD40 activation of 
antigen-nonspecific bystander B cells results in cellular activation and induction of Fas 
expression. Interaction with Fas-ligand expressed on the activated T cell leads to B cell 
apoptosis. (B) Similarly, antigen-specific B cells are activated with cell activation and 
increased Fas expression. However, protection from apoptosis induction via Fas-FasL is 
mediated by a signal delivered by the surface Ig receptor (BCR), with subsequent 
activation and differentiation processes such as isotype switching. (C) Germinal center B 
ceIls, as weIl as anergic B cells obtained in different tolerance models, seem to be 
susceptible to apoptosis through BCR cross-linking. This induction of apoptosis seems to 
be independent of Fas-FasL. The B-T cell immune synapse in the presence of a 
combination of CD40L and cytokines (lL-4) prevents this form of apoptosis, allowing for 
further differentiation ofthese B cells (depictedfrom van Iwoten, C. et al. (90)). 
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II.D.2.CD27: Role in B Cell Maturation 
Another important member of the TNF-R family for B lymphocytes activation is 
CD27. CD27 expression is restricted to a subpopulation of B lymphocytes and has been 
proposed as a marker for memory B cells 104. Two populations in the human tonsils and 
PB have been differentiated based on CD27 expression 105. Flow cytometric analysis 
revealed that CD27 molecules were expressed on GC Band memory B cells but not on 
naïve B cells 105-109. Although several studies attribute its expression to memory B cells, 
one study describing its expression on different subsets of tonsillar B ceIls, showed that it 
was highly upregulated on plasma cells. However, they identified plasma cells based on 
CD38 and CD20 expression (CD38+CD20+) only. Defining the expression ofIgD would 
have allowed differentiation of CD38+ plasma cells from CD38+IgD+ GC founder cells 
which could be present in their culture system. Morphological analysis reveals distinct 
features for CD27 positive cells which are larger cells with abundant cytoplasm compared 
to CD27 negative B cells which are smaller with scant cytoplasm 106. The ligand for 
CD27, CD70, is a member of the TNF family. CD70 is expressed by a large fraction of 
activated T lymphocytes as well as activated B ce Ils, and seems to play a role in the 
regulation of CD27 function at late stages of B cell differentiation into antibody-
producing plasma cells 110,111. In functional in vitro assays, CD27+ B cells are rapidly 
activated and can produce higher levels of IgA, IgM, IgG and IgG subclasses compared to 
CD2T B cells 106,112. Furthermore, CD27/CD70 interaction has been shown to specifically 
augment IgE secretion as the use of an anti-CD70 mAb completely abrogated this effect 
in B cell cultures. Only purified CD27+ B cells secreted IgE following stimulation with 
IL-4 and anti-CD40. In addition, CD27/CD70 interaction enhanced B cell proliferation in 
the presence ofIL-4 or IL-4 plus anti-CD40 113. CD27 signaIs through TRAF molecules 
(TRAF-2, -3 and -5) 82, and has common signaling pathways with CD40, such as NF-KB 
and c-Jun kinase 114,115. Finally, the presence of somatic mutation, which is a definitive 
marker of memory B cells 116, has been described on CD27+ IgD+ PB B cells with the 
majority of cells carrying mutated V -region genes 107,116 
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CD27 signaling is also important for the generation of plasma cells: CD27+ 
memory B cells differentiate into plasma cells as a result of contact with CD27 ligand 
(CD70) transfectants in conjunction with interleukin-l0 (IL-lO) 112, Staphylococcus 
aureus Cowan strain (SAC) + IL-2 117, or IL-4 + CD40 signaling 113. This strongly 
suggests an important role for this molecule, which seems to be upregulated by 
CD40/CD154 interaction in PBL 99,118, in memory B cell differentiation and Ig 
production. Does CD27 synergize preferentially with a specific yet unidentified cytokine 
like CD40 with IL-4 to mediate B cell differentiation downstream of CD40? 
A number of other B-cell molecules are also important for contact-dependent 
costimulation of T cells, without being direct transducers of B cell activation signaIs. 
These inc1ude: CD80, CD86, 4-1BBL, OX40L, and B7.h 78,119. 
II.D.3. The Role of cytokines in mature B cell differentiation 
Once B cells are activated by signaIs through costimulatory molecules and antigen 
receptor, cytokines play important roles in their subsequent differentiation. The fate of B 
cells upon activation also seems to depend on B-celllineage and maturation stage 120. The 
cytokine milieu is crucial for determining the outcome of an immune response after T-
cell-B-cell interaction. Most studies have focused on the cytokines produced by T cells. It 
appears that B cells might have a more active role in determining the fate of immune 
responses as well 121-123. It has been shown recently that Th cells direct secreted cytokines 
into two distinct pathways: one towards the immunological synapse, and another 
multidirectional pathway. Using intracellular cytokine staining, the authors show that the 
secretion of IL-2, IFN-y, IL-3 and IL-IO is mainly concentrated at the immunological 
synapse in activated Th cells. By contrast, TNF, IL-4, CCL3, and CCL5 were observed to 
be scattered throughout the cell 124. One of the best characterized cytokines produced by 
T cells in the context of a productive T -B collaboration is IL-4, which is required for 
IgGl and IgE production in c1assic Th2 responses 125. IL-4 is secreted by T cells into T-B 
synapses during cognate interaction with B cells 126. Upon treatment with IL-4, naïve B 
cells have enhanced survival, increased expression of costimulatory CD80/86 molecules, 
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and are primed for MHC class II/Ig-a/J3 signaling 125,127. The presence of IL-4 with B 
cells cultured on CD40 ligand-transfected cells induces a strong proliferative response in 
these cells \03. Other T cell-derived cytokines involved in B cell differentiation include 
IL-2, IL-3, IL-6, and IL-IO 120. IL-13, a Th2 cytokine, acts at different stages of the Bcell 
maturation pathway: (a) it enhances the expression of CD23/Fc epsilon RII and class II 
MHC antigens on resting B cells; (b) it stimulates B cell proliferation in combination with 
anti-Ig and anti-CD40 antibodies; and (c) it induces IgE synthesis. Thus, the spectrum of 
the biological activities of IL-13 on B cells largely overlaps with the role ascribed to IL-4 
128. It has also been demonstrated that IL-6 plays an important role in stimulating the 
proliferation and Ig secretion of isotype-switched B cells 129. IL-9, a pleiotropic Th2 
cytokine recently described, has been recently shown to modulate immunoglobulin 
production in PBL, however, its precise role in human B-T cell interactions remains to be 
addressed. 
III. The Thlffh2 Response 
Once a B cell has 'made the choice' to become a memory or a plasma cell, what 
determines the activation requirements for the strength and direction of the effector 
immune response? Can a cytokine influence the outcome of a B-T cell interaction or is it 
the T cell that dictates the type of antibody produced? It is generally accepted that Thl 
type responses include mainly cellular immune responses with antibodies produced of the 
IgG2a subtype and a prevalence of cytotoxic effector T cells, whereas Th2 immune 
responses influence humoral immunity relying on the production ofIgE and IgG 1 130,\31. 
Cytokines are involved in modulating the immune response with a predetermined bias 
towards a Th 1 or a Th2 response. IL-4 promotes Th2 clonaI expansion and limits the 
proliferation ofThl cells and, conversely, IFN-y enhances Thl-cell growth, but decreases 
Th2-cell development (Figure 8) 132,133. Several factors such as antigen type and/or load, 
route of infection, antigen presentation, the microenvironment at the time of infection or 
antigen exposure may altematively greatly influence the type of immune response. The 
area is certainly open for debate with more than 6000 papers published thus far 
addressing Thl/Th2 regulation. 
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Figure 8: Thl and Th2 immune responses 
Depending on the cytokine 'milieu' Th cells can differentiate along the Thl or Th2 
pathway. IL-l2 drives Thl cells, whereas IL-4 promotes Th2 cells. The presence ofIFN-y 
and IL-4 plays a dual role as inhibitors of the other subset, and autocrine factors. Thl 
enhances IgG2a synthesis by B cells through IFN-y, whereas Th2 cells induee B-cell IgE 
and IgG 1 production through IL-4. Th 1 cells destroy intracellular pathogens and protect 
against organ-specifie autoimmunity through IFN-y. Th2 cells are anti-helminthic and 
increase allergie reaction through IL-4, IL-5 and IgE. 
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The provision ofT cell help in the secondary lymphoid follicles is a crucial step in 
the development of memory B cells and their differentiation to antibody producing cells. 
Do Th land Th2 cells have equal chances in achieving contact with high affinity 
centrocytes and driving their selection and differentiation? Evidence obtained thus far 
remains controversial. Results published by Randolph, et al. have documented that 
differential expression of the chemokine receptor CCR7 on Th2 ce Ils, which do not 
normally express the chemokine receptor, results in their localization in the follicles in a 
Th l-like pattern and inhibits their participation in B eell help in vivo but not in vitro 134. 
Another study, published reeently, argues against their tindings that T cell help in the 
follicles is restrieted to Th2 cells and presents data showing that in vivo polarized Thl 
and Th2 cells clonally expand to similar levels and migrate into B cell follicles in which 
they support B cell clonai expansion and Ab production to a similar degree 135. Moreover, 
they present direct evidence that in vivo polarized, IFN-y seereting Th 1 eells migrate into 
B cell follicles to interact with Ag-specifie B cells. Other studies have also described the 
ability of Thl cells to support B eell responses 136-138. Critieally, cytokines expressed in 
polarized immune responses contribute largely to peripheral B-cell development, with a 
potential exacerbation of the host's immune response leading to disease. 
The expression of several diseases can depend on whether Th 1 or Th2 
lymphocytes predominate in response to an Ag challenge 139. Robinson et al. 140 showed 
that allergie reaetions involving IgE and mast eells could be due to the development and 
activation of allergen-speeific TH2 cells. Subsequently, other clinical and experimental 
studies strongly implicated Th2 lymphocytes, and the cytokines they produce such as IL-
4, IL-5, IL-13 and recently IL-9, in the pathogenesis of allergic asthma 141-143. 
IV.loterleukio-9 
IV.A. Cellular Source 
IL-9 was tirst identified as a mou se T eell growth factor 144. It was designated as 
P40, since its prote in was purified at this molecular weight. It was isolated as a factor that 
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supported permanent Ag-independent growth of helper T cell clones 144-146, from the 
supematant ofhelper T celllines stimulated with Con A or phorbol esters. The cloning of 
the cDNA was performed following screening of the cDNA library obtained from these 
helper T cells clones with a probe prepared based on the sequence of the purified protein 
P40 144. In vitro expression studies have shown that Th2 lymphocytes could produce IL-9, 
adding it to the Th2 cytokine family 147. Parallel studies had shown that bone marrow-
derived mast celllines (BMMC) proliferated and produced the inflammatory cytokine IL-
6, in response to a mast cell growth-enhancing activity (MEA) 147. More recently, murine 
BMMC were reported to produce a significant amount of IL-9 prote in in response to 
stimulation with IL-l, and IgE-Antigen complexes. Moreover, the study shows that a 
dramatic potentiation of IL-9 mRNA and prote in expression occurs following treatment 
with kit ligand or IL-lO 148. A variety of other cell types including mast cells, eosinophils, 
and neutrophils were shown to produce IL-9. Further, upon stimulation ofhuman PBMCs 
with anti-CD3 antibodies, IL-9's expression was induced 147,149,150. The presence of IL-9 
transcripts has been detected in human peripheral blood eosinophils, and eosinophil-
differentiated HL-60 cell lines 150. However, the release of the protein was significantly 
present only in eosinophils from asthmatic subjects. Moreover, stimulation of these cells 
with either TNF -Œ or IL-l resulted in increased IL-9 levels in culture supematants, 
whereas eosinophils from healthy control subjects did not show the same effect. 
Furthermore, IL-9 mRNA has been described in bronchial biopsy specimens of 
asthmatics 151. Finally, although neutrophils from asthmatics were shown to express IL-9, 
the frequency ofIL-9 mRNA+ neutrophils remained low 152. 
IV.B Gene Structure 
IL-9 belongs to a family of 4-helix bundle cytokines which also includes IL-2, IL-
3, IL-4, IL-6, IL-7, and IL-15. The gene encoding human IL-9 maps to the Th2 cytokine 
gene cluster region that also includes IL-4, IL-5, IL-13, IL-3 and granulocyte-
macrophage-colony stimulating factor (GM-CSF) on the long arm of chromosome 5 
(5q3l-35) (Figure 9) 153-156. These factors have been implicated in allergie inflammation 
157,158 These genes map to a syntenic region in mice on chromosome Il, exeept for the IL-
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9 gene, which maps to mouse chromosome 13 159. Both human and murine IL-9 genes 
show similar genomic organization with 5 exons and 4 introns spanning approximately 4 
kb 160. In humans, the 5' flanking region contains specifie binding sites for the activator 
prote in 1 (AP-l) and (AP-2) transcription factors. The 5' promoter region was also shown 
to have a consensus sequence for IFN-regulating factor 1, as weIl as sequences common 
to IL-l, IL-2, IL-3, IL-4, IL-5, IL-6, and GM-CSF genes suggesting common regulatory 
pathways 161. 
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Figure 9: Map of the cytokine gene c1uster on human chromosome 5 
Human chromosome 5 (near segment q31), distances are approximate. The human IL-9 
gene spans 4 kb on chromosome 5q31-q35 region; mIL-9 maps to chromosome 13; mIL-
3, 4, and 5 are on chromosome II. IL-9 cDNA sequence is composed of 5 exons and 4 
introns. 
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Linkage studies performed on human populations 154,162 and in mice, as weIl as 
expression profiles 151 have proposed IL-9 as a candidate gene for asthma. The IL-9 gene 
expression seems to be under the control of different transcription factors. The IL-9 
promoter region have been shown to bind to the activator of protein-1 (AP-1) and AP-2 
transcription factors 160. However, the minimum sequence required for IL-9 gene basal 
and indu cible expression induction was described in human T cell leukemia virus type-1 
transformed T cells, C5MJ2. It contained an NFKB site, an upstream 20 bp adjacent site, 
c-Jun, and potentially new proteins (35 kd) 163. The expressed protein is a 14 kD 
glycoprotein. It has a signal sequence of 18 amino acids (aa), with a mature form of 144 
aa. The IL-9 protein contains a high proportion of cationic aa residues and 10 cysteines 
and has 4N-linked glycosylation sites. The homology between human and murine IL-9 is 
69% at the nucleotide lev el and 55% at the prote in level l60• 
IV.C. Regulation ofIL-9 Expression 
The requirement for T cell activation for IL-9 to be produced may be explained by 
the induction of IL-9 expression by IL-2 in human T cells 149,164}. In fact, a cascade of 
cytokines is involved in IL-9 expression: IL-2 induces IL-4 production, which in tum 
leads to IL-1 0 production when combined with IL-2, and consequently IL-2, IL-4 and IL-
10 induce IL-9 production. The induction of IL-9 production in mast cells by cytokines 
such as IL-l, IL-lO and kit ligand, point to an important role played by IL-9 in the 
development of late asthmatic reaction 165,166. In addition, a few reports have linked 
allergen challenge to an increase in IL-9 positive cells in the bronchoalveolar lavage fluid 
in patients with atopic asthma 167. 
IV.D. The IL-9 Receptor 
The human IL-9 receptor belongs to the hematopoietin receptor superfamily. IL-9 
exerts its action by binding to the IL-9R, which is a heterodimer consisting of the IL-9Ra 
chain and the IL-2Ry chain (Figure 10). This common y chain is used by other cytokines 
such as IL-2, IL-4, IL-7 and IL-15 168. The human IL-9Ra gene is composed of Il exons 
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and 10 introns ranging approximately over 17 kb 169. Interestingly, a linkage for asthma 
and bronchial hyperresponsiveness has also been reported for the IL-9R gene locus 170. 
In humans, expression of the IL-9Ra. chain has been documented on different cell 
types involved in the pathogenesis of asthma. IL-9R alpha-chain protein expression was 
detected in cultured human airway smooth muscle (ASM) ce Ils, primary cultured ASM 
cells, as weil as bronchial smooth muscle cells within biopsies of asthmatics 171. 
Polymorphonuclear neutrophils expressing the IL-9Ra. chain have been detected in 
patients with airway dysfunction and damage 172-174. In particular, RT-PCR analysis 
showed the presence of IL-9Ralpha-chain mRNA in PMN RNA preparations from 
asthmatic patients. 
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Figure 10: The IL-9R Complex and Signaling Components 
IL-9 transduces its signal by sharing the common gamma chain with other cytokines IL-2, 
IL-4, IL-15, and using a specifie alpha chain. Upon ligation with IL-9, JAK-l, JAK3, and 
Tyk2 can be activated and the signal is then propagated to STAT-l, 3, and 5 to induce 
proliferation, differentiation or survival. 
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Using FACS analysis, surface expression of IL-9Ralpha was detected on PMNs 
freshly isolated from asthmatics, and to a lesser extent on normal controls. In addition, 
prote in expression of IL-9Ralpha was also detected in peripheral blood and 
bronchoalveolar lavage PMNs 175. Finally, bronchial biopsy specimens from asthmatic 
patients had a higher level of IL-9R expression compared to controls thus confirming the 
potential role of IL-9 in asthma 151. Moreover, a role for IL-9 in other inflammatory 
diseases is suggested from a study showing a significant increase in the expression of the 
IL-9R in the upper airways of cystic fibrosis patients compared to controls 176. 
The first study to de scribe the presence of the IL-9R on murine cells shows no 
response for fresh non-activated or Concanavalin A-activated splenic B cells to 
stimulation with IL-9, along with no significant binding indicating either an absence or 
the presence of a low level of the receptor on these cells 177. In another study in mice, 
transgenic expression of IL-9 leads to an expansion of the B-l lymphocyte population 
with a majority of the expanded ce Ils belonging to the B-l b subpopulation (IgM~ac-
1 +COY). Authors of the study demonstrate that the IL-9R is preferentially expressed on 
BI cells both CD5+ as weIl as C05-, in contrast, it is barely detectable at the surface of 
IgM+ cells from the spleen which are B2 cells 169. Hence, these two studies seem to 
indicate that in mice IL-9R expression is mainly found on BI cells which are 
characterized by their peritoneal and pleuropericardial location and their ability to 
respond to T-independent antigens 178. 
IV.E. IL-9-induced Signalling 
As depicted in figure 10, IL-9 signaling involves activation of Janus kinase 
(JAK)l and JAK3 kinases which are associated with the IL-9 specific receptor and 
gamma chain respectively 179. Jak kinases establish docking sites for SH2 and PTB 
domain containing signalling proteins such as ST A T transcription factors and insulin 
receptor substrate (IRS) adaptor proteins by phosphorylation of the receptor tyrosine 
residues. Signal transducer and activator of transcription (ST AT) 1, ST A T3 and ST A T5 
179-182 are activated by IL-9. 3,5,8STAT5 activation was shown to be required for IL-9 
42 
dependent growth and transformation of lymphoid cells. Vpon mutation of the ST A T5 
binding site of the IL-9 receptor, ST AT activation was greatly decreased and proliferation 
was inhibited. Expression of a constitutively active form of ST A T5 results in IL-9 
independent cellular growth ofa transfected B cellline 183. A specific role for STATI and 
STA T3 in differentiation gene induction has been shown by introducing point mutations 
in amino acids in the ST AT binding region in the IL-9R 181. In addition, IRS 1 and IRS2 
are required for mitogenic responses 180,184-187. Phosphatidylinositol 3'-kinase (PI3K) and 
Grb-2 interact with tyrosine-phosphorylated IRS proteins subsequently. PI3K activity is 
necessary for the IRS-1I2-mediated proliferative effect of IL-9 187. In T cells and mast 
cells, IL-9 upregulated the expression ofBCL3 gene in a JAKISTAT dependent pathway. 
BCL3 activates NF-lCB leading to the transcription of a variety of genes implicated in 
stress and immune responses 188. On the other hand, IL-9 signal attenuation seems to 
occur through induction of cytokine-inducible SH2-containing prote in (CIS), and the 
suppressor of cytokine signaling (SOCS)-2 and 3 in a STAT-dependent manner. 
However, only SOCS-3 inhibited IL-9-induced signal transduction 189. 
IV.F. Biological Effects ofIL-9 
Interleukin-9 and the a-chain of the lL-9 receptor (IL-9Ra) have been shown to 
affect the differentiation pathway of different cell types including human T cells 189, 
eosinophils 190, mast cells, and B cells 147,191. 
IV.F.l. Effect on T ceUs 
Using a chimeric human-mouse fetal thymic organ culture, a role for IL-9 in early 
thymic T cell development was demonstrated. The use of a neutralizing antibody to the 
IL-9Ra chain greatly reduced the number of thymocytes derived in vitro from human 
CD34+ hemopoietic precursor cells, leading to decreased cell numbers of CD4+CD3-CDS-
CDI+ progenitor cells and subsequently CD4+CDS+ double positive (DP) thymocytes 192. 
However, as deletion of the IL-9 gene in mice did not affect T cell development as 
assessed by flow cytometry, whereby the expression of different T cell markers was 
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equivalent in wild type and knock-out mice, one may question whether human and 
murine systems are similar enough to allow us to conclude that IL-9 helps maintaining T 
cell survival but is not essential for T cell development 193. Data obtained using transgenic 
mice indicate that IL-9 overexpression increases susceptibility to T -ce Il lymphoma 
development following irradiation or administration of low doses of mutagens 191,194 
whereas in vitro, only murine T lymphoma and myeloid leukemia cells proliferate in 
response to IL-9 and not normal cells 191,195. This evidence points to a role for IL-9 in T 
cell survival and tumor formation. 
IV.F.2. Effect on Eosinophils 
Interaction between IL-9 and eosinophils was examined in humans by purification 
of mature peripheral blood eosinophils. The expression of the IL-9Ra chain was detected, 
and eosinophils were protected from apoptosis in the presence of IL-9. In the presence of 
IL-5 and IL-3, IL-9 potentiated the development of eosinophils from human CD34+ cord 
blood cells and human promyelocytic leukemia cell line (HL-60). In vivo, locally instilled 
IL-9 increases eosinophil count in BAL fluid 196. Moreover, IL-9 transgenic mice were 
found to display significantly enhanced eosinophilic inflammation 197 suggesting that IL-9 
may potentiate eosinophil function in vivo. IL-9 induced the expression of IL-5Ra on 
human CD34+ cord blood progenitor cells 190. Eosinophils were also found to be expanded 
in IL-9 transgenic mice in an IL-5 dependent pathway 198. Strikingly, IL-9 knock-out 
mice were able to develop eosinophilic inflammation in a similar degree to their wild-
type littermates 199, suggesting that in the murine system and possibly in humans 
redundancy exists with respect to IL-9's effects on inflammatory cells. 
Eosinophils were also shown to have the capacity to synthesize and release IL-9 
200, this was observed in human peripheral blood eosinophil RNA preparations from 
subjects with atopic asthma, as weil as in the eosinophil-differentiated HL-60 cell line. 
Moreover, cultured human peripheral blood eosinophils from asthmatic subjects 
synthesize and release IL-9 prote in, which is upregulated on stimulation with TNF -alpha 
and IL-l beta. 
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IV.F.3. Effeet on Mast eeUs 
IL-9 was shown to affect other cell types such as mast cells, whereby IL-9 
synergized strongly with stem cell factor to induce their growth and differentiation 201. IL-
9 was found to synergize with IL-3 in promoting the proliferation of bone marrow-
derived mast cells 147. IL-9 was not only found to potentiate mast cell growth but it also 
played a role as a differentiation factor. In vitro, IL-9 induced mou se mast cell proteases 
transcripts expression inc1uding mMCP-1 202, mMCP-2, mMCP-4, as weIl as granzyme B 
203. Moreover, IL-9 increased the expression of the a-chain of the high affinity IgE 
receptor (FceRIa) and stimulated IL-6 production 204. It was also shown that BMMC were 
potent producers of IL-9 in response to IgE-allergen complexes challenge, thus 
implicating IL-9 in the regulation of the asthmatic inflammatory responses 166. Studies on 
IL-9-transgenic mice have shown a mast cell expansion correlating with higher serum 
concentrations ofmMCP-1 205. On the other hand, deficient IL-9 gene expression in mice 
decreases the number ofmast cells in a model of Schistosoma infection 193. 
IV.F.4. Effect on B eeUs 
It has been shown that IL-9 can potentiate IL-4-induced IgG and IgE production 
from normal human PBMC, as weIl as from LPS stimulated murine B lymphocytes 206,207. 
Moreover, transgenic mice that constitutively express IL-9 were shown to have an 
increase in both baseline and antigen-specific immunoglobulin concentration for aIl 
isotypes tested 169. 
Allergen-exposed IL-9 transgenic mice exhibit many features of human asthma, 
and have increased IgE production 197. In addition, intratracheally instilled IL-9 in lungs 
of C57BL/6 mice induced a significant elevation in total serum IgE in these mice 196. 
However, it is not c1ear whether IL-9 specifically increases the production of IgE isotype 
or induces a global increase in Ig levels. These data strongly suggest a role for IL-9 in 
enhancing antibody production, and potentially modulating B cell growth and/or 
differentiation (Figure Il). 
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Figure Il: EfTect of IL-9 on B CeUs 
Based on studies performed on PBMCs, IL-9 may affect B cell differentiation and 
antibody production. While its role in the periphery has been approached, studying the 
effect of IL-9 in the context of B-T cell interaction in the lymphoid follicles with the 
potential modulation of immunoglobulin production will help elucidate its role in the late 
phase ofthe T -ce Il dependent immune response within immune synapses. 
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IV. F.S. Pleiotropic effects ofIL-9 
IL-9 overexpresslOn studies amplified the direct effect of IL-9 and/or its 
synergistic effect with other cytokines resulting in its pleiotropic effects on different 
hematopoietic cell lineages leading to lymphomagenesis, increased immunoglobulin 
secretion, mastocytosis, eosinophilic infiltration, airway inflammation, and subepithelial 
collagen deposition 194,208. In addition, IL-9 synergizes with TNF-(l to induce IL-8 
secretion, and synergizes with IL-13 to increase eotaxin release from airway smooth 
muscle cells in vitro 209. Moreover, IL-9 synergizes with IL-5 in driving eosinophilic 
maturation ofprecursors (Figure 12) 190,198. 
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Figure 12: Pleiotropie Effeets of IL-9: Potential Role in the Allergie Inflammatory 
Response. 
IL-9 has been shown to exert an effect on a variety of immune and non immune cells. The 
effects range from modulation of T cell survival to induction of mucin expression from 
epithelial cells. IL-9's pleiotropic effects on key players of the allergic response may 
constitute a susceptibility factor for atopy and allergie inflammation. (depieted from 
Renauld, 1. C. et al. (216» 
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IV.G. Role ofIL-9 in the Allergie Inflammatory Response 
Human and mouse genetic studies implicate IL-9R expression and IL-9 in the 
pathogenesis of asthma and allergie inflammation 154,162. Indeed, overexpression of IL-9 
in mice whether systemically 194, or under the control of a lung-specific promoter 208 
results in a myriad of symptoms which resemble the phenotype of asthma including 
mucus overproduction, subepithelial fibrosis, increased intraepithelial mast ce li s, lung 
eosinophilia, airway hyperresponsiveness, and increased responsiveness to Ag stimulation 
197,208. Concomittant to IL-9's enhancement effect increased production ofIL-4, IL-5, and 
IL-13 is observed. In a murine asthma mode l, IL-4 and IL-5 were necessary for IL-9-
induced eosinophilia, and IL-13 was necessary for lung inflammation and mucus 
production 210. 
The effect of IL-9 on different inflammatory and structural cell types has been 
studied in the context of asthma (Figure 12) I3. Functional studies showed that stimulation 
of PMNs from asthmatics with IL-9 resuIts in the release of IL-8 in a concentration-
dependent manner. Anti-IL-9 neutralizing Abs suppressed this effect 175. Airway 
epithelial cells are activated by IL-9 and produce several chemokines, proteases, ion 
channels and selective mucin genes 211,212. Further, IL-9 induced mucin production in 
allergic airway disease both in vitro and in in vivo studies 213. Airway smooth muscle ce lis 
are also a target for IL-9 which acts by amplifying the potential for these cells to recruit 
eosinophils and neutrophils into the airways through upregulation ofthe IL-5Ra receptor, 
the TNF-a induced secretion ofIL-8 209, and IL-13 induced eotaxin release 209. Hence, IL-
9 exerts a wide range of biological actions affecting not only inflammatory cells but also 
structural cells (Figure 12). IL-9 seems to be acting by synergizing with other 
inflammatory cytokines. Interestingly, the observed effects seem to be restricted or more 
pronounced in asthmatic human subjects which is consistent with the genetic studies 
performed in mice, whereby higher expression levels of IL-9 correlated with 
susceptibility to bronchial hyperresponsiveness 154, strongly suggesting a complex role for 
this cytokine in the pathogenesis of allergic inflammation and asthma. This has been 
substantiated by a series of studies in humans showing an increased expression of IL-9 in 
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bronchial biopsies from asthmatic patients when compared to control biopsies 151, and a 
role for IL-9 in airway hyperresponsiveness and mucus overproduction in asthmatics 212. 
Specifically, an upregulation of the human calcium-activated chloride channel hCLCAl 
in mucus producing epithelium of asthmatics compared to control subjects has been 
observed with a strong correlation between hCLCAl and IL-9 found 214. 
Moreover, IL-9 may promote systemic anaphylaxis reactions, acting at both the 
sensitization and effector stages, but is not absolutely required for this process as a 
murine passive model of systemic anaphylaxis shows. IL-9 expression is linked to 
increased susceptibility to fatal anaphylaxis when mice are sensitized by immunization 
against OVA or DNP-BSA 215. 
The effect of blocking IL-9 activity in the allergic response is controversial. 
Neutralizing IL-9 with a mAb decreased the IgE response, pulmonary eosinophilia, goblet 
cell hyperplasia, airway epithelial hyperplasia, and airway hyper-responsiveness in 
DBA/2 x C57BL/6 FI mice 216. In another study, anti-IL-9 Ab administration to 
previously sensitized mice was able to prevent airway hyperreactivity and lung 
eosinophilia upon aerosolized antigenic challenge 217. By contrast, in a similar OVA-
induced asthma model, IL-9-deficient mice showed no decrease in allergic pulmonary 
airway hyperactivity, eosinophilia, goblet cell hyperplasia, or specific IgE 199. Finally, in a 
typical Th2 infection model, anti-IL-9 vaccination prevented Trichuris muris expulsion 
and blood eosinophilia, but not the IgE response 218. 
IV. H. IL-9 and Disease 
Besides its role during immune responses, its growth factor and antiapoptotic 
activities on multiple transformed cells suggest a potential role in tumorigenesis. Indeed, 
IL-9 overexpression induces thymic lymphomas in mice 191,194, and IL-9 release is 
associated with Hodgkin disease 219,220 and HTL V -1 transformed T cells in humans 
161,221,222. Moreover, in vitro, dysregulated IL-9 response can result in autonomous cell 
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growth and malignant transformation of lymphoid cells associated with constitutive 
activation of the Jak/STAT pathway 183. 
ln addition to IL-9's described role in allergy and asthma, IL-9 was also shown to 
be a susceptibility factor in Leishmaniasis whereby IL-9 neutralization in L.major-
infected nonhealer BALB/c mice doubled the time span until pathological disease 
progression occurred. This was translated in a reduction of detrimental Th2/type 2 
responses with an observed shift toward protective Th 1 immune responses 223. 
V. Allergie Inflammation 
The complex coexistence of three different features defines the pathophysiology 
of asthma, namely: 1) reversible intermittent airway obstruction 2) 
bronchoyyperresponsiveness (BHR), defined as an increased sensitivity of bronchial 
smooth muscle cells to bronchoconstrÏctors such as histamine or cholinergic agonists, and 
3) chronic bronchial airway inflammation 224. The inflammatory process of asthma is 
characterized by the accumulation of Th2 lymphocytes and eosinophils in the airways. 
The secretion of cytokines, particularly IL-4, IL-B, IL-5, and IL-9 is mediated by Th2 
cells and contributes to the development of asthma by recruitment and accumulation of 
different inflammatory cellular types to the primary inflammatory lesion of asthma. In 
human asthma, expression of both IL-9 and its receptor was reported recently, and IL-9 
mRNA expression correlated with the airway responsiveness to metacholine 151. 
V.A. Cytokines in Allergie Inflammation 
Once the existence of Thl and Th2 cells have been established, accumulating 
evidence pointed to a role for Th2 cells in the incidence of atopic diseases based on 
experiments in mice and humans 225,226. Conversely, Thl cells preferentiallyproduce IL-2 
and interferon y (IFN-y), thereby promoting cellular immune responses including the 
activation of cytolytic T cells, and the killing of intracellular pathogens by macrophages. 
Indeed, it is the Th2 cells that recognize allergens via their T cell receptors (TCRs) and 
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release interleukins in their surrounding milieu that play a role in recruiting a variety of 
inflammatory cells such as IgE antibody-producing B cells (IL-4, IL-13), mast cells (IL-4, 
IL-IO), and eosinophil granulocytes (IL-5) in allergie inflammation (reviewed in 226). 
Experimental evidence obtained from murine models of allergy and asthma showed that 
transfer of Th2, but not of Thl, cells into recipient mice induces airway eosinophilia, 
mucus hyper-secretion, and airway hyperresponsiveness (AHR). Finally, transgenic mice 
that overexpress the Th2 cytokines in the airway epithelium exhibit airway eosinophilia, 
mucus hyperproduction, AHR, and airway remodeling 226. In humans, CD4+ T cells 
producing IL-4, IL-S, and IL-13 have been identified in BAL and airway biopsies from 
patients with asthma. These cytokines are also secreted in the airways of patients with 
mi Id or asymptomatic disease 140,227. Moreover, the number of Th2 lymphocytes is 
augmented in the airways of patients with allergic asthma following antigen challenge 
140,227,228. Based on these data, it has been proposed that Th2 cells trigger an inflammatory 
response that results in asthma. 
This proposaI can be substantiated by a number of findings involving the Th2 
cytokines IL-4, IL-S, IL-9, and IL-13 which can account directly or indirectly for the 
great majority of pathophysiological manifestations of allergic inflammation. IL-5 and 
chemokines attract eosinophils to target tissues, while IL-4 induces the rolling on, and 
adhesion to, endothelial cells of circulating eosinophils 229. IL-13 is responsible for mucus 
hypersecretion by mucus cells, and induces metaplasia of mucus cells 230. IL-4 and IL-13 
stimulate fibroblast growth and chemotaxis, as weIl as the synthesis of extracellular 
matrix proteins 231. In addition, IL-4 and IL-13 are key factors in immunoglobulin 
production by B lymphocytes particularly isotype switching to IgE. 
V.B. Regulation of the IgE Response 
As B cells are taught to fight infection by producing and refining weapons that are 
used for normal host immune reactions, disease emerges from their use against allergens 
present in the environment. This triggers a series of events that lead to atopic diseases 
namely allergic rhinitis, asthma, and atopic dermatitis. 
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Patients suffering from atopic diseases have elevated serum levels of antibodies of 
the IgE isotype, which is normally produced in response to parasitic infections. The 
clinical symptoms of atopy result from the release of inflammatory mediators (e.g 
histamine and leukotrienes), enzymes and cytokines subsequent to the crosslinking of IgE 
on tissue mast cells by its high-affinity Fc receptor, FCERI 232. The presence of FCERI has 
been demonstrated on other cell types including Langerhans cells 233, a subset of 
monocytes \05, and dendritic cells 234. Other cell types were shown to express FCERI albeit 
with sorne controversy about their surface expression: eosinophils 235,236, neutrophils 175, 
and platelets 237. Importantly, it was observed that the modulation of FCERI on the se cells 
depended on serum IgE levels, with important implications for the biology of atopy and 
the design of therapeutic intervention modules 238. IgE plays also a role in antigen 
presentation by allergen uptake and binding through the low affinity Fc receptor, FCERII, 
on B cells as weIl as other immune cells 232. The low affinity IgE receptor (CD23) 
(FcERII) has been identified on B ceIls, monocytes, follicular dendritic ceIls, Langerhan's 
ceIls, eosinophils, platelets, and airway smooth muscle cells 239,240. FCERII, (CD23) 
controls IgE secretion and transport 241. Rence, understanding the regulation of IgE 
production is crucial to the elucidation of the mechanisms underlying IgE-related diseases 
such as asthma. 
IgE production is controlled at the level of IgE isotype class switching which 
depends on the development of Th2 cells. As a number of cytokines and molecules 
discussed above influence this process (Figure 13), the Th2 cytokine IL-9 described thus 
far as an 'atopy' related gene may contribute to the regulation of IgE production alone or 
by synergizing with other Th2 cytokines. 
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Figure 13: Molecular Control of the IgE Response 
The established paradigms attribute induction of IgE production to IL-4 and IL-13 
mainly, although other cytokines such as IL-9 may play a role in this regard. CD40-
CD154, and CD86-CD28 interactions as weil as other cognate interactions possibly 
through CD27-CD27L promote IgE production through direct effects on T cell and B 
cells. Transcription factors such as STAT-6, induced by IL-4Ra, and NF-lCB, induced by 
CD40 promote IgE production by initiating epsilon transcript synthesis and class 
switching. 
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VI. IL-9 in the Immune Synapse 
LD ceIls, representing mainly a population of GC ceIls, will be examined in our 
system for the expression of the IL-9Ra chain. It is actually at the level of the immune 
synapse in the GC of the secondary Iymphoid follicles that B-T cell interaction occurs at 
the edge of their respective are as 242 with a variety of cognate molecules involved. At this 
stage, a role for CD40 in isotype switching is crucial for the development of the memory 
B cell response. Different key players have been documented: IL-4, a Th2 cytokine plays 
a major role in driving IgE production. The persistence of the memory B cell was shown 
to be independent ofpersisting immunizing antigen 243, suggesting that BCR-independent 
signais may operate at the immune synapse to sustain selected memory B cells. Is IL-9R 
expressed on GC ceIls, and if so what is the phenotype of IL-9R positive ceIls? Does IL-9 
affect the survival of selected centrocytes thus increasing the number of memory B cells 
exiting the GC reaction? What effect does it exert in the presence of other cytokines such 
as IL-4 in the modulation of IgE production? Are there other molecules than IL-4 
involved in IgE production that may interact with IL-9? 
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THE SIS HYPOTHESIS 
IL-9 plays a role in B-T cell interactions in the context of Ge B cell maturation, and 
modulates memory B cell differentiation and IgE production in inflammatory responses. 
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THE SIS OBJECTIVES 
The major objectives of this work were to characterize the expression of the IL-
9Ra chain on human tonsillar B cells at different maturational stages in the germinal 
center, and determine its effect on B cell differentiation and survival among high 
expressors. 
With respect to the expression of the IL-9Ra chain, we were interested in 
investigating the expression levels on B cells of human tonsils following fractionation 
into different subpopulations. This was of interest as it shows the potential role of IL-9 in 
the maturation pathway of antigen-driven GC B cell differentiation. This is an important 
issue since this process leads ultimately to B cell differentiation into an immunoglobulin 
producing plasma effector cell or a memory B cell with the potential to isotype switching. 
The human IL-9 gene has been mapped together with the other Th2-type cytokine 
genes IL-4, IL-5, and IL-13 in the 5q31-33 region of chromosome 5; this segment of the 
genome represents a candidate region for genes that determine susceptibility to bronchial 
hyperresponsiveness and atopy. Therefore, it was of interest to investigate the 
contribution of IL-9 to B-T cell interactions and its effect on IgE production in light of its 
potential role in health and disease as a switch factor in immunoglobulin production. 
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CHAPTER 2: MATERIALS AND METHODS 
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B-cell purification 
Fresh B lymphocytes were isolated from human tonsils discarded following 
surgery. Hypertrophied tonsils from pediatrie patients of variable ages were obtained after 
routine tonsillectomy. Tonsils were selected as a source of B cells for our study, because 
human tonsils receive repeated antigen stimulation, and display aIl stages of peripheral B 
cell development; hence, they constitute an ideal tissue to determine IL-9R expression at 
different stages of B cell maturation. The tonsils were thoroughly minced, resuspended in 
wash medium consisting of RPMI 1640 (Gibco, BRL Canada) supplemented with 2% 
FCS (Hyclone Laboratories Inc.), 50 U/ml penicillin, 50 J,!g/ml streptomycin, and 
amphotericin B (1/500 w/v) from Life Technologies (Burlington, ON, Canada); and then 
layered onto a Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden) gradient. Tonsil 
lymphocytes were separated by rosetting with neuraminidase-treated sheep red blood 
cells and Ficoll-Paque density centrifugation. Monocytes were removed from the E-
rosette-negative fraction by adherence depletion; the remaining B cells were routinely 
demonstrated to be > 98% pure on flow cytometry by CD20 staining, with <1% CDI4+ 
and <1 % CD3+. 
Percoll gradient centrifugation 
Adherence-depleted B cells were layered onto Percoll gradients (Pharmacia 
Biotech). A 90% Percoll solution was prepared by dilution with lOX PBS (Gibco, BRL). 
Dilutions of 60%, 50%, 30% and 20% were prepared by diluting the 90% solution with 
lXPBS. Dilutions of 90%, 60%, 50% and 30% were layered in 15 ml Falcon tubes 
(Becton Dickinson, La JoIla, CA), according to the methods of Liu et al. 244 and Suzuki et 
al. 245. The cell suspension (25xl06 cells at lOx106 cells/ml) was mixed 1:1 with 20% 
Percoll and applied to the top of the gradient. Following centrifugation (20 min, 4°C, 
2400 rpm), the fractions were aspirated; cells recovered below the 60% layer were 
considered high density ce Ils which are resting B ceIls; between the 50 and 60% layers, 
medium density or cycling centroblasts and centrocytes and low density cells GC cells 
were recovered from the 30-50% layers 244,246. 
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Anti-CD40 antibody purification 
Culture supematants of G28.5 hybridoma cell line were filtered on a 0.45 !lm 
filter before passing on an anti-mouse IgG agarose column (Sigma, Saint Louis, USA). 
The column was washed with PBS (pH 7.3; no azide), and the flow adjusted to - 50-60 
ml/hour. The filtered supematant was passed twice over the column and the flow-through 
was collected. After washing the column with PBS until OD ~ 0, bound antibody was 
eluted with a 15 ml of 100 mM glycine-HCl 0.15 nM NaCI pH 2.5. High OD280 tubes 
were then pooled, and neutralized with 1 M Tris pH 9.5 to pH 7.0. The elute was 
concentrated with Amicon Concentrator, filtered on a 0.22 !lm membrane, and stored in 
aliquots at -80°C. 
Cell Culture 
Purified LD B cells were cultured in RPMI 1640 supplemented with 10% FCS, 5 
mg/ml L-glutamine, 50 U/mL penicillin, and 50 Ilg/mL streptomycin (lnvitrogen). To 
assess IgE secretion, Percoll-fractionated tonsillar LD B lymphocytes were cultured in 
24-well plates (lml/well) at a concentration of 0.5x106 cells/ml in the presence of anti-
CD40 (l !lg/ml) and IL-4 (400 U/ml) al one or in the presence of IL-9 (10 ng/ml) in 
duplicates. Cell supematants were harvested on the 7th and 14th day of culture and kept 
at -20°C until use. Altematively cells were stained with different antibodies (anti-CD27, 
anti-CD38, anti-IgD, anti-IL-9Ra) and processed for flow cytometry at days 1,6, and 10. 
Immunocytochemistry 
Cytospin slides were prepared from tonsillar B cells, fixed in 4% 
paraformaldehyde for 20 min at room temperature, and washed with 0.05 M Tris-HCI-
buffered isotonic saline, pH 7.6 (TBS). After drying, the slides were stored at -20°C 
before immunocytochemistry. 
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The cytopreparations were washed with Tris-buffered saline (TBS) (pH 7.6). After 
saturation for 10 min with a Universal Blocking solution (DAKOCytomation Inc., 
Mississauga, Ontario, Canada), the cells were incubated with mouse anti-IL-9R-a (R&D 
Systems, Cedarlane Laboratories Ltd, Ontario Canada) or isotype-matched control each at 
5 Jlg/ml overnight at 4°C. After washing, rabbit anti-mouse Ig (1 :60) (DAKOCytomation) 
was added for 30 min at room temperature followed by alkaline phosphatase anti-alkaline 
phosphatase (1 :60) (DAKOCytomation.) for 30 min at room temperature. After washing 
with TBS, the slides were developed using Fast Red (Sigma, Toronto, ON) and 
counterstained with hematoxylin Gill II (Surgipath Canada Inc.) and examined by 
microscopy. 
Immunohistochemistry 
Cryostat sections of human tonsillar tissue were fixed in acetone:methanol. 
Sections were blocked for 10 minutes with a Universal Blocking solution, briefly washed 
with TBS, and incubated in a humid chamber overnight at 4°C with a rabbit anti-human 
IL-9Ra antibody (11100) (Santa Cruz Biotechnology, California USA), and a mou se anti-
human CD20 (11100) (DAKOCytomation, Inc. Canada). After washing in TBS, sections 
were incubated with a second layer antibody (horse anti-mouse IgG Biotin 11100 (Vector 
Labs Canada Inc., Burlington, Ontario, Canada) for CD20 and swine anti-rabbit IgG 
biotin (DAKO) 1/100) for IL-9R. Following another wash in TBS, sections were 
incubated with StreptAvidin-alkaline phosphatase (11200 in TBS) (DAKOCytomation 
Canada Inc.) for CD20 and Horse Radish Peroxidase complex for IL-9R for 30 min 
(DAKOCytomation Canada Inc.). This was followed by incubation in the alkaline 
phosphatase substrate Fast Red for 20 minutes, revealing bound mAb as a red deposit, 
and 5 min incubation with the chromagen solution 3,3' -diaminobenzidine (DAB) 
(DAKO) + H202 revealing the IL-9Ra chain. Slides were counterstained with 
hematoxylin, dehydrated, and mounted for viewing. 
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Immunofluorescence 
Slides were processed for immunofluorescent labeling as described earlier for 
immunohistochemistry. Primary monoclonal antibodies directed against CD19 (1:10) 
(Pharmingen) were labeled with Alexa Fluor 568 using the Zenon Red kit from Molecular 
Probes (Portland, OR). Monoclonal Ab against IL-9Ra (1 :50) (R&D) was followed by an 
FITC-conjugated goat anti-mouse IgG Ab (Pharmingen). Slides were mounted after 
washing in TBS in PermaFluor mounting medium from Immunon and viewed with a 
confocal fluorescence microscope. 
Flow cytometric analysis 
For flow cytometric analysis, B cells were incubated with saturating 
concentrations of surface marker staining antibodies. Three-color analysis was performed 
with unlabeled IL-9R mAb and FITC-goat anti-mouse Ab, directly PE-conjugated mou se 
anti-human IgD, and APC-conjugated mou se anti-human CD38 (BD Biosciences, 
Mississauga, Ontario, Canada). PE-conjugated IgG 1 isotype was used as a control of 
specificity for IgD staining, APC-conjugated IgG 1 isotype was used as a control for 
CD38, and mouse IgG 1 followed by FITC-conjugated goat anti-mouse was used as a 
control for specificity for IL9R FITC staining. After staining, cells were resuspended in 
2% paraformaldehyde and 5xl05 cells/sample were analyzed by FACSCalibur using Cell 
Quest software. 
For flow cytometric analysis, B cells were incubated with saturating 
concentrations of surface marker staining antibodies. Two-color analysis was performed 
with unlabeled IL-9R mAb and FITC-goat anti-mouse Ab, and directly PE-conjugated 
mouse anti-human CD27 (BD biosciences). PE-conjugated IgGI isotype was used as a 
control of specificity for CD27 staining, and mouse IgG 1 followed by FITC-conjugated 
goat anti-mouse was used as a control for specificity for IL9R FITC staining. After 
staining, cells were resuspended in 2% paraformaldehyde and 5x105 cells/sample were 
analysed by F ACSCalibur using Cell Quest software. 
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STATs phosphorylation analysis 
lxl06 LO cells were stimulated with IL-9 (10 ng/ml) for 15 min. Cells were fixed 
at 37°C (for 10 min) by adding formaldehyde to a final concentration of 2%. After 
centrifugation, tubes were placed on ice for 2-3 min, then 1 ml 100% ice co Id methanol 
was added. Cells were placed on ice for 30 min, then processed for antibody labeling. 
Phosphorylated STAT-5 was labeled with a phosphospecific antibody (rabbit polyclonal) 
that detects the phosphorylated tyrosine residue (Tyr 694) associated with activated 
STAT-5 (Cell Signaling Technology, Inc. Oanvers, MA, USA), Phosphorylated STAT-3 
with an antibody that detected phosphoTyr 705, and anti-phospho- STATl (Tyr 701). The 
antibodies were used at a 1/100 dilution. Cellular fixation and immunostaining were 
performed as described previously 247. After staining, intracellular levels of 
phosphorylated STATs were measured by flow cytometry. 
Immunoblotting 
Total unfractionated tonsillar B cells as well as low density B cells were incubated 
with IL-9 (R&O) for 15 min. Following the reactions, cells destined for immunoblotting 
were washed once with ice-cold PBS and lysed in lysis buffer (1 % NP-40, 0.5% Sodium 
Deoxycholate, 0.1% SOS, 25 mM Tris-HCI pH 7.5,5 mM EOTA, 50 mM NaF, 0.1 mM 
Na3V04). Whole celllysates (15 Jlg total prote in) boiled in 2 x Laemmli buffer (125 mM 
Tris-HCI pH 6.8, 4% SOS, 25% glycerol, 10% 2-[3-mercaptoethanol) were then resolved 
on 12% SOS-PAGE and immunoblotted with anti-phosphotyrosine monoclonal antibody 
4G10 (Upstate Biotechnology, NY, USA), anti-phospho-STAT3 (Tyr 705), or anti-
phospho-STAT5 (Tyr 694), anti-phospho-STAT1 (Tyr 701) (Cell Signaling Technology, 
Inc. Oanvers, MA, USA). 
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Proliferation Assay 
Low density B cell proliferation was assessed by thymidine incorporation. Cells 
were cultured for 72h in a 96-well plate in the presence of lOng/ml of rhIL-9 alone or in 
combination with an antibody to the BCR (aIgM 2 ug/ml). Altematively rhIL-4 was 
added alone (400 U/ml) or in the presence of aIgM at a final cell density of 1 X 105 
cells/ml in a volume of200 JlI/well in 96-well round-bottom plates for 3 days at 37°C in a 
humidified atmosphere with 5% CO2. Then cells were pulsed with 1 uCi/well for 18h, 
thymidine incorporation levels were measured by liquid scintillation counting. 
Altematively cells were cultured in the presence of IL-9, IL-4 and anti-CD40 mAb (l 
Jlg/ml) in similar conditions. 
Immunoglobulin assay by enzyme-linked immunosorbent assay 
Purified LD tonsillar B cells were cultured with or without aCD40 (l Jlg/ml) and 
IL-4 (400 U/ml) in the presence or absence ofIL-9 (lOng/ml) at a final cell density of 5 
X 105/ml in a volume of 1 ml/well for 14 days at 37°C in a humidified atmosphere with 
5% C02. The cultured supematants were harvested and added to Ninety-six-well plates 
(Costar, Coming Corp, Acton, Mass) coated ovemight at 4°C with 5 llg/mL rat anti-
human IgE (Biosource, Camarillo, Calif) in 0.05 mollL carbonate-bicarbonate buffer, pH 
9.6. After washing 3 times with PBS/O.l % Tween 20, the plates were blocked with PBS 
plus 0.5% gelatin (Sigma) for 2 hours at 37°C and then incubated for 2 hours at 37°C 
with cell culture supematants or seriaI dilutions of human IgE standards. After washing, 
biotinylated goat anti-human IgE (Biosource) diluted 1: 15,000 was added and incubated 
for 2 hours at 37°C. The plates were washed, and then streptavidin-horseradish 
peroxidase conjugate (Biosource) diluted 1: 10,000 in blocking buffer was added. After 
incubation for 1 hour at 37°C, tetramethylbenzidine (Zymed Labs Inc, South San 
Francisco, Calif) was added, and the plate was incubated for 10 minutes at room 
temperature. The reaction was stopped with phosphoric acid (Sigma), and absorbance was 
measured with an ELISA reader at 450 nm. The limit ofIgE detection was 50 pg/mL. 
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Apoptosis Assay 
To detennine the effect of IL-9 on tonsillar B cell survival, LD B cells were 
stimulated with immobilized CD40L monoclonal antibody for 72h al one or in the 
presence of IL-9, IL-4 or both cytokines for the last 24h of culture. Apoptosis was than 
induced with a monoclonal antibody (CH-11) to Fas receptor for 6h. After Fas-induced 
apoptosis, the cells were collected, washed twice with phosphate-buffered saline (PBS) 
and analyzed for the annexin V /PI double staining to measure phosphatidylserine 
translocation on cell membranes (Biosource International, California, USA). Levels of 
Fas receptors were detennined by staining with anti-Fas FITC (R&D, Minneapolis) and 
analyzed by FACS. 
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CHAPTER3: RESULTS 
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1) Tonsillar B cells' phenotype 
In order to ascertain the purity and homogeneity of the B cell population studied, 
cells were purified from tonsils as described in materials and methods and stained for 
flow cytometry to detect the presence of monocytes (CDI4), T ce Ils (CD3), and assess the 
percentage of B ce Ils (CD20) present as weIl as their maturation stage (sIgM). Results 
found indicate clearly that the majority of cells purified are CD20+ sIgM+ B ceIls, with a 
few cells CDI4+ and CD3+ (Figure 1). 
2) IL-9R is expressed on tonsillar B cells 
The expression of the IL-9 receptor alpha chain (IL-9Ra.) on B cells has not been 
weIl characterized. To address this207,248, we assessed the expression of the human high 
affinity a. chain of the IL-9R on freshly isolated purified human tonsillar B ceIls, because 
human tons ils receive repeated antigen stimulation, and display aIl stages of peripheral B 
cell development; hence, they constitute an ideal tissue to determine IL-9R expression at 
different stages of B cell maturation. Immunocytochemistry was performed on cytospins 
of unfractionated B cells purified from three independent tonsils, using an affinity-
purified monoclonal antibody to the alpha chain of the IL-9R. Multiple tonsillar B cells 
stained positive for the IL-9Ra. chain as shown in figure 2 in one representative sample 
(Figure 2A, b). Panel (a) of figure 2 shows the absence of specific staining wh en an 
isotype-matched control antibody is used. Moreover, flow cytometry analysis of total 
tonsillar B cells from different tonsils stained with a mAb to the IL-9Ra. chain confirmed 
our microscopic observation, showing positive reactivity with a mean percentage 
positivity of 19% IL-9R positive cells amongst purified tonsillar B cells as depicted in 
Figure 2B. The result shown is representative of3 different tonsils (mean 21.33±3.21SD) 
69 
3) Immunohistochemistry of IL-9R expression on tonsillar B cells 
These findings prompted us to further investigate the precise localization of the 
IL-9R positive B cells within the lymphoid foIlicIe. For this purpose, 
immunohistochemistry was performed on sections of human tonsils. Using double 
staining with anti-IL-9Ra (HRP staining developed with DAB, brown) and anti-CD20 
(APAAP staining developed with Fast Red, red) (Figure 3,4) as weIl as with anti-IL-9Ra 
and anti-CD19 (immunofluorescence) (Figure 5), we found that CD20+/CD19+ B cells 
within the secondary lymphoid follicIes (Figure 3A), and especially cells on the edge of 
these follicies (Figure 3A,b; Figure 4; Figure 5A), displayed IL-9Ra. This is cIearly 
observed with the colocalization ofIL-9R and CD20 (Figure 3A b brown), and CD19 and 
IL-9R (Figure 5A red and green) as detected by confocal microscopy for 
immunohistochemistry and fluorescent staining respectively. Comparing the intensities of 
expression of IL-9R inside the foIlicIe versus the edge of the secondary lymphoid 
foIlicIes, we observed that although IL-9R positive cells are found in both areas, cells on 
the edge of the foIlicIes display a higher frequency of expression. Taken together, these 
results suggest that the IL-9R is principally expressed on foIlicular mantle B cells. 
4) Percoll jractionation 
B cells purified were layered onto a Percoll gradient and B cell subpopulations 
were isolated corresponding to Germinal center low density cells (LD) (between 30 and 
50%), Centroblasts and Centrocytes medium density B cells (MD) (between 50 and 60%), 
as weIl as high density cells (HD) (above 60%) (Figure 6). 
5) The distribution of IL-9R expression among B cell subsets 
We th en determined IL-9R expression on purified populations of tonsillar B cells 
at different stages of their maturation within lymphoid foIlicIes. This was made possible 
by fractionating human tonsillar B lymphocytes using discontinuous Percoll density 
gradients. Using this method, we obtained three populations: low density (recovered in 
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the 30-50% Percon fraction), which represents mainly germinal center B cens, medium 
density (50-60%), which are primarily centroblasts and centrocytes, and high density 
(>60%) or mature/resting B cens 246. Using flow cytometry, IL-9Ra. expression was 
higher in the low density or germinal center fraction of the B cens (39%), as compared to 
medium density (22%), and high density fractions (16%) (Figure 7A). Results presented 
are representative ofthree independent tonsils (with a mean and SO values for LO 36.1% 
± 4.82, MD 17.5% ± 4.56, HO 18.4% ± 2.24). 
6) Phenotype ofGC cells expressing IL-9R 
To further characterize the phenotype of germinal center cens expressing the IL-
9R, three color flow cytometry was used to trace the IL-9R expression on human tonsillar 
B cens through their progression in the fonicular germinal centers from naïve GC cens (F 
M B cells) (C038·IgO+), to founder GC cens (C038+IgO+) to memory B cens and plasma 
cens (C038-IgO- and C038+IgO- respectively) 54. Upon analysis of C038+ and IgO+ 
cens for IL-9R expression, we could clearly distinguish two distinct populations based on 
IgD expression: IgO·IL-9R1o and IgO+IL-9Rhi cens (Figure 7B). IL-9R expression was 
highest within the IgO+C038+ founder GC cells (57%) (Figure 7c), and the FM B cens 
which are IgO+C038· (32.0%) (Figure 7a). Thus, IL-9R expression corresponds to the 
entry of naive FM B cens to the GC and their selection as founder cens. In contrast, GC 
cens that have lost IgD expression and are C038+, i.e centroblasts and centrocytes, show 
no significant expression of IL-9R (4.0%) (Figure 7b). Surprisingly, a population of 
memory B cens (IgO·C038) is positive for IL-9R (18.0%) (Figure 7d), indicating a 
possible role for IL-9 in secondary immune responses. The results shown are 
representative of three independent experiments with a mean value for IgO+C038-
(29.4% ± 6.22), IgO+C038+ (54.3 ± 16.22), IgDTD38- (19.7% ± 8.53), IgO-CD38+ (8.1% 
± 4.82). 
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7) IL-9 induces tyrosine phosphorylation in LD cells 
To as certain the functionality of the IL-9R expressed on GC LD B cells, we 
assessed the total protein tyrosine phosphorylation on total unfractionated tonsillar B cells 
as weIl as on low density B cells, purified from tonsils, following activation with IL-9 for 
15 min. As shown in figure 9A, specific upregulation of tyrosine phosphorylation is 
observed in IL-9 stimulated LD cells and not in unstimulated LD cells (lanes 6 and 5). 
This upregulation is diminished upon addition of a neutralizing antibody ta IL-9 (lane 7). 
The Jurkat cellline constitutively activated was used as a positive control (shown in lane 
2). Tonsillar B cells stimulated with IL-9 did not show any increase of tyrosine 
phosphorylation compared to untreated B cells. Amplification products specific for 13-
actin were of similar intensity between all samples, which suggests the equality of protein 
samples loaded. Results presented are representative ofthree independent experiments. 
8) STAT activation following IL-9 stimulation of LD cells 
In order to dissect further the signaling pathways involved in this activation, we 
sought to determine the activation of Signal Transducer and Activator of Transcription 
(STATs) following IL-9 stimulation of GC cells. ST AT -5 belongs to the family of ST AT 
transcription factors, which mediate the cellular response to a variety of cytokines 
inc1uding IL-9. Using specific antibodies that detect the phosphorylated tyrosine residue 
associated with activated STAT-5 (Tyr 694), we performed immunostaining of IL-9 
stimulated LD cells and expression levels ofphosphorylated STAT-5 by flow cytometry. 
The results show an upregulation of STAT-5 phosphorylation following IL-9 stimulation 
specifically in LD cells and not in total B cells, MD or RD cells as shown by flow 
cytometry (Figure 8A). Conversely, immunoblotting failed to show any significant 
upregulation of ST AT5 phosphorylation in stimulated LD ce Ils in comparison to 
unstimulated cells (Figure 9B), whereas in Jurkat T cell line, activation of STAT5 was 
visible (Figure 9B). Since flow cytometry amplifies the signal detected at the single cell 
level, it allows a higher sensitivity than immunoblotting. 
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Other STATs that have been linked to IL-9 signaling include STATl and STAT3. 
Staining for tyrosine phosphorylated residues in STATI (Tyr 701) and STAT3 (Tyr 705) 
in total tonsillar B cells and LD ce Ils demonstrate a specific activation of STAT3 and not 
STATl in LD cells in the presence ofIL-9 as shown by immunoblotting (Figure 9B), and 
flow cytometry data (Figure 8B). This is particularly interesting as STAT5 
phosphorylation has been linked to cellular growth and proliferation 183, whereas STAT3 
and STATI are upstream of differentiation genes 181 in IL-9 signaling events. In B cell 
responses, ST A T5 has been reported recently to be phosphorylated in a subset of tonsillar 
B cells, its activation was linked to upregulation of BCL6, a transcription factor involved 
in memory B cell differentiation 249. In mice, STAT3 has been shown to be required for 
T-dependent IgG plasma differentiation 250. Taking into account the species difference, a 
similar role in human B cells seems likely. 
These results demonstrate for the first time the expression of a functional IL-9R 
on GC B cells. Our findings demonstrate the presence of a functional IL-9R on primary 
human GC cells at physiologic levels of the receptor, in the absence of overexpression of 
the IL-9R as has been done in other studies to increase Stat activation signal and enhance 
its detection levels 179,251. 
9) Synergistic effect of IL-9 on IL-4-induced IgE production 
We have previously shown by immunohistochemistry and FACS analysis that 
tonsillar LD cells purified by Percoll fractionation have the highest expression of IL-9R, 
with a preferential expression on IgD+ and memory B cell populations in germinal 
centers. 
To determine the effect of IL-9 on IgE production by LD cells, we cultured 
Percoll-fractionated LD cells in the presence or absence of anti-CD40 with or without IL-
4, IL-9 or both cytokines. IL-9 alone in the presence of anti-CD40 does not induce IgE 
production as compared to treatment with anti-CD40 and IL-4 (Figure 10). However, 
addition of IL-9 to anti-CD40 and IL-4 potentiates IgE production with up to a five fold 
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increase in the amount of IgE produced as determined by ELISA on day 14 of cell culture 
(from 2972.4 ± 412.66 in the presence of anti-CD40 and IL-4 to 15253.5 ± 146.37 upon 
addition of IL-9) (Figure 10). The amount of IgE obtained is maximal at day 14 of cell 
culture, the synergistic effect of IL-9 is observed starting day 7 of the culture. Hence, 
although IL-9 is unable to drive B cell differentiation per se, it greatly potentiates IL-4's 
activity on B cells by upregulating IgE production. 
10) IL-9 does not potentiate LD B cell proliferation 
We asked whether this observed effect for IL-9 was due to an increase in cell 
number. To address this question cellular proliferation assays were set up to determine 
IL-9's role. Using incremental doses ofIL-9: 10, 50, and 100 ng/ml, we show that IL-9 
does not induce a significant LD B cell proliferation on its own in the presence of anti-
CD40 as compared to cells cultured in the presence of anti-CD40 alone irrespective of the 
dose of the cytokine used (Figure lIA). However, these cells respond to IL-4 as shown 
by their incorporation of triutated thymidine readings. As shown in Fig Il B, IL-9 had no 
effect on LD cellular proliferation whereas the presence of IL-4 induced proliferation. In 
order to verify the possibility that IL-9 may synergize with IL-4 in inducing LD B cell 
proliferation, we stimulated LD B cells with IL-9 in the presence of anti-CD40 and IL-4. 
There was no potentiation of the proliferative response in the presence of IL-9 compared 
to IL-4 al one (Figure lIB). To ascertain that IL-9's effect on LD cellular proliferation 
does not vary with different stimuli, we used a-lgM to induce cellular proliferation in LD 
cells. Results show (Figure Il C) that IL-9 does not affect cellular proliferation in the 
presence of anti-lgM, whereas IL-4 induces cellular proliferation in LD cells in these 
conditions. Hence, IL-9 does not seem to play a role in LD cellular proliferation 
irrespective of the stimulus. 
Il) IL-9 inhibits Fas-induced LD B cell apoptosis 
LD cells were stained for Fas expression. The expression of the Fas receptor was 
stable during the culture period of 72h (Figure 12). To determine the effect of IL-9 on 
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tonsillar B cell survival, LD B cells were stimulated with immobilized anti-CD40 
monoclonal antibody for 72h alone or in the presence of IL-9, IL-4 or both cytokines for 
the last 24h of culture. Apoptosis was than induced with a monoclonal antibody (CH-11) 
to Fas receptor for 6h. Assessment of apoptosis in B cell cultures was done by measuring 
phosphatidylserine translocation on cell membranes using Annexin V staining. As 
expected, CD40-activated LD B cells treated with anti-Fas antibody alone showed an 
induction of apoptosis. Treatment of equivalent cells with IL-9 or IL-4 resulted in a 
decrease in Fas-induced apoptosis; however, the induction of apoptosis was only 
completely abrogated when both IL-9 and IL-4 were present in culture (Figure 13). 
Therefore, data gathered from these experiments demonstrate for the first time that IL-9 
not only rescues CD40-activated LD B cells from Fas-mediated apoptosis, but also 
potentiates IL-4's protective role with respect to counteracting induced apoptosis. 
12) IL-9R and CD27 are upregulated on CD40-stimulated LD B ells 
We sought to determine the phenotype of cells with increased IgE production. Are 
these cells IL-9 respondents throughout the cell culture period (14 days), do they 
differentiate into a memory or plasma cell phenotype? For this purpose, we stained for the 
IL-9R expression at different time points at Days 1, 6, and 10 of cell culture. Our results 
show that IL-9R expression is upregulated through CD40 stimulation and maintained 
throughout the culture period. However, the presence of IL-4 and not IL-9 appreciably 
contributed to an increase in IL-9R expression at Day 6 of cell culture (Figure l4A). Cells 
were also stained for CD27 expression which showed a pattern similar to the observed IL-
9R upregulation whereby the observed increase correlated specifically with CD40 and IL-
4 stimulation (Figure 14B). Interestingly, the increase in CD27 expression occurred 
nearly totally on IL-9Ra positive cells highly suggesting a link with augmented IgE 
production. Analysis of IL-9Ra expression on peripheral blood lymphocytes from normal 
donors is shown in Figure 15. Nearly the totality ofIL-9R+ cells express CD27, this is of 
high interest in light of the described role ofCD27 as a memory B cell marker. 
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Figure 1: Tonsillar B Cells' Phenotype. 
Tonsillar B cells were purified from freshly isolated tonsillar cells by rosetting using 
neuraminidase treatment. Purity of B cell population was assessed by flow cytometry by 
single staining for CD 14, CD3, CD62L, and the B cell markers CD20 and sIgM. Cells 
obtained from three independent tonsils were assessed, and results shown represent their 
mean value with SD bars shown: for n=3, isotype (2.98±2.20%), CD14 (l.067±O.93%), 
CD3 (3.39±1.45%), CD62L (49.66±3.21%), CD20 (87.67±2.51%), sIgM (91.0±2.64%). 
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Figure 2: Detection of IL-9Ra on tonsillar B ceUs. 
A) Immunocytochemistry for IL-9Ra on tonsillar B ceUs. IL-9Ra chain expression in 
unfractionated tonsillar B cells. a, absence of immunoreactivity signal when using an 
isotype-matched control antibody as the primary antibody b, immunocytochemical 
detection (red color) of IL-9Ra in a cytospin preparation of purified tonsillar B cells 
stained with a mouse affinity purified mAb antihuman IL-9R-a chain (isotype IgG 1) 
followed by rabbit anti-mouse Ig (1 :60) and alkaline phosphatase anti-alkaline 
phosphatase (l :60). The slides were developed using Fast Red and counterstained with 
hematoxylin Gill II. B) FACS for IL-9Ra expression on tonsillar B ceUs using anti-
IL-9Ra monoclonal antibody. IL-9Ra cell surface expression on tonsillar B cells was 
assessed by flow cytometry. Results of analysis of Ixl05 cells are shown and are 
representative of 3 individual tonsillar B cells' fractions with a mean expression of 
21.33% and SD of 3.21%. Percentages shown correspond to the proportion of cells that 
are IL-9Ra high. 
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Figure 3: Immunohistochemistry for IL-9Ra on tonsillar tissue sections. 
IL-9 receptor alpha chain expression and CD20/CD 19 B cell markers on tonsillar tissue 
sections were assessed by immunohistochemistry. Alkaline phosphatase anti-alkaline 
phosphatase (AP AAP) double immunostaining was used for IL-9Ra and CD20 
expression. A) secondary follicle can be seen with double immunostaining(Magnification 
20X); a- 40x magnification for inside the follicle; b-edge of the follicle (40x); c-Negative 
staining for CD20 and IL-9Ra. as represented outside the follicles. 
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Figure 4: Secondary Follicle. 
IL-9 receptor alpha chain expression and CD20 B cell markers on tonsillar tissue sections 
were assessed by immunohistochemistry. Alkaline phosphatase anti-alkaline phosphatase 
(AP AAP) double immunostaining was used for IL-9Ra and CD20 expression. Secondary 
follicle can be seen with double immunostaining (Magnification 20X) with the 
hematoxylin blue counterstain delineating the edge ofthe follicle 
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Figure 5: Immunohistochemistry for IL-9Ra on tonsillar tissue sections by confocal 
microscopy. 
Tissue sections of tonsils were processed for immunohistochemistry as described in 
materials and methods. For Confocal microscopy, monoclonal antibodies for IL-9Ra and 
CD 19 were used as primary antibodies, conjugated thereafter to goat anti-mouse PITC 
and zenon antibodies Alexa fluor 568 respectively. A) Follicle rim is shown with staining 
for IL-9Ra positive cells (green) and CD19 a B cell marker (red); B) Follicle staining 
shows seant IL-9Ra expression on B cells. 
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Figure 6: Percoll gradient. 
Percoll density gradient centrifugation yields four layers leading to the isolation of three 
tonsillar B cell subtypes. The LD B cell subset (the fraction between 30-50%), MD (50-
60%), and HD (> 60%). 
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Figure 7: A) IL-9Ra. expression on tonsillar B cell subsets. 
Cell surface expression of IL-9Ra. chain on tonsillar B cell subsets from Percoll gradient 
seperation. Percentages shown indicate the IL-9Ra. high cells within the LD, MD, and 
HD B cells as obtained from fractionation of B cells using a discontinuous Percoll density 
gradient. This is representative of three distinct experiments with a mean of 36.1±4.8% 
for LD cells, MD (l7.5±4.6%), and HD B cells (18.4±2.2%) B) FACS for IL-9RalIgD 
and CD38 expression on LD B cells. a)Three-color F ACS staining of LD tonsillar B 
cells' fractions. LD cells were labeled as described in Materials and Methods with anti-
IL-9 receptor alpha chain, anti-CD38 and anti-IgD. Results of analysis of lx105 cells are 
shown for one representative tonsil from 3 individual tonsillar B cells' fractions. A 
representative dot plot is shown for IgD and CD38 positive cells, and histograms for the 
selected gates are shown: a) FM: IgD+CD38· mean 29.4± SD 6.2% b) GC: IgD·CD38+ 
8.1±4.8% c) Founder GC: IgD+CD38+ 54.3±16.2% d) Memory IgD·CD38· 19.7±8.5%. 
Percentages for each histogram correspond to the proportion of cells that are IL-9Ra. 
positive amongst different gated populations as identified on the dot blot representing 
total triple stained LD B cells. b) IL-9Ra positive cells in IgD CD38 IL-9R stained LD 
cells are given as a percentage of positive cells within gated populations the results shown 
are representative of three individual tonsillar cells analyses. 
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Figure 8: A) STAT5 phosphorylation. 
Using a phosphospecific antibody that detects the phosphorylated tyrosine residue 
associated with activated STAT5, we performed an immunostaining ofIL-9 stimulated or 
not tonsillar B cells, LD, MD and HD cells and analysed expression levels of 
phosphorylated STAT5 by flow cytometry. A polyclonal antibody conjugated to FITe 
was used to stain 1 x 1 06 cells. Results shown are representative of three independent 
experiments (see table 2 attached). This demonstrates phosphorylation of STAT5 
following addition of IL-9 to the LD B lymphocyte fraction. B) STATI & STAT3 
phosphorylation. Staining for the phosphorylated tyrosine residues associated with 
activated ST A Ts 1 & 3 was performed on LD cells unstimulated and stimulated with IL-
9, expression levels were analysed by flow cytometry. 
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Fig 9: A) Immunoblot of tyrosine phosphorylation for IL-9 stimulated B ceUs. 
Tyrosine phosphorylation of unfractionated tonsillar B cells as well as LD B cells both 
unstimulated and stimulated with IL-9 (10 ng/ml) for 15 minutes is shown. Cells were 
incubated with or without IL-9 and/or IL-9 plus anti-IL-9 for 15 minutes, washed with 
ice-cold PBS and cell pellets were lysed in lysis buffer for 20 mins on ice. 15 J.lg of 
prote in was run on an SDS polyacrylamide gel then blotted for phosphorylated tyrosine 
using 4G 1 0 or anti-actin antibodies. Figure is representative of three independent 
experiments, and demonstrates an increase in the total level of tyrosine phosphorylation 
in IL-9 stimulated LD B cells. D) Immunoblot of STATl, 3, and 5. Immunoblotting for 
STATs 1,3, and 5 is shown for total B cells as weIl as percoll-fractionated LD cells. Non-
stimulated and IL-9 stimulated ceIls are lysed and immunoblotted with anti-
phosphotyrosine antibodies for specifie ST A Ts. Jurkat cells are shown as positive 
controls and actin levels for equal samples loaded is shown. 
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Figure 10: Synergistic Effect ofIL-9 on IL-4-Induced IgE Production 
Percoll-fractionated tonsillar LD B lymphocytes were cultured in 24-well plates 
(1ml/well) at a concentration of 0.5x106 cells/ml in the presence of anti-CD40 (1 ~g/ml) 
and IL-4 (400 V/ml) alone or in the presence ofIL-9 (10 ng/ml). Cell supematants were 
harvested on the 7th and 14th day of culture and kept at -20°C until use. IgE was assayed 
by ELISA, values are given in pg/ml, SD bars are shown. Results of a representative 
experiment are shown (n=4) 
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Figure 11: A) IL-9 Does Not Potentiate CD40L-Activated LD B Cell Proliferation. 
Low density B cell proliferation was assessed by thymidine incorporation. Cells were 
cultured for 72h in a 96-well plate in the presence of 10, 50 or 100 ng/ml of rhIL-9 alone 
or in combination with an antibody to CD40 (1 ug/ml). Altematively rhIL-4 was added 
alone (400 U/ml) or in the presence of anti-CD40 at a final cell density of 1 X 105 
cells/ml in a volume of 200 ,....l/well in 96-well round-bottom plates in triplicatas for 3 
days at 37°C in a humidified atmosphere with 5% C02. Then cells were pulsed with 1 
uCi/weIl for 18h, thymidine incorporation levels were measured by liquid scintillation 
counting. 
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Figure 11: B) No Synergistic Effect for IL-9 on IL-4-Induced LD B Cell 
Proliferation 
LD B cells were cultured as described above, LD cells were cultured alone in the 
presence ofanti-CD40, IL-4 or in the presence ofboth IL-9 and IL-4 cytokines. 
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Figure 11: C) IL-9 Does Not Potentiate IgM-Activated LD B Cell Proliferation 
Low density B cells were cultured for 72h in a 96-well plate in the presence of lOng/ml 
of rhIL-9 alone or in combination with an antibody to the BCR (anti-IgM 2 ug/ml). 
Alternatively rhIL-4 was added al one (400 U/ml) or in the presence ofanti-IgM at a final 
cell density of 1 X 105 cells/ml in a volume of 200 ill/weil in 96-well round-bottom 
plates for 3 days at 37°C in a humidified atmosphere with 5% C02. Then cells were 
pulsed with 1 uCi/well for 18h, thymidine incorporation levels were measured by liquid 
scintillation counting. 
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Figure 12: Fas expression on LD cells. 
Fas expression is shown both at time 0 and at 72h of culture. LD cells were stained 
directly for Fas expression or cultured for 72h before labeling. Results are representive of 
two experiments with a mean expression level of 38.5 % ± 0.70 at time 0 and 38.5 % ± 
2.12 at 72h. 
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Figure 13: IL-9 Inhibits Fas-Induced LD B Cell Apoptosis 
To determine the effect of IL-9 on tonsillar B cell survival, LD B cells were stimulated 
with immobilized CD40L monoclonal antibody for 72h alone or in the presence of IL-9, 
IL-4 or both cytokines for the last 24h of culture. Apoptosis was than induced with a 
monoclonal antibody (CH-11) to Fas receptor for 6h. Assessment of apoptosis in B cell 
cultures was done by measuring phosphatidylserine translocation on cell membranes 
using Annexin V staining. 
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Figure 14: Al IL-9R Expression during 10 days culture 
LD cells were stained with a monoclonal antibody to the IL-9Ra chain following isolation 
from tonsils, at days 1, 6, and 10. Cells were cultured in the presence or not of anti-
CD401IL-4 and/or IL-9 for the indicated periods. Results shown are representative of 
three independent experiments. BI IL-9Ra CD27 Expression. Cells cultured were double 
stained for IL-9Ra and CD27. 
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Figure 15: PBMC staining for IL-9Ra. 
Staining for IL-9Ra on PBMCs purified from freshly obtained blood from non-atopic 
donors. IL-9Ra+CD19+ were found to be 25.60% of total cells purified with a SD of 
7.34%; IL-9Ra+CD19+CD27+ cells are 25.54% +/-SD 8.32%. Results represent the 
mean of three different experiments. 
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CHAPTER 3: DISCUSSION 
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We have examined the expression ofIL-9Ra chain on tonsillar LD B cells. These 
mostly GC cells are implicated in B-T cell interactions occurring during the maturation 
process of memory B cells, with a variety of cognate molecules involved in the immune 
synapse. Data obtained in vitro from human PBMC as weIl as in vivo from mice indicate 
a possible effect for IL-9 and its receptor on B cell maturation. We therefore addressed 
IL-9Ra expression levels on human B lymphocyte subpopulations purified from tonsils, 
to better define IL-9's role in B cell differentiation in the germinal center response. In 
humans, to our knowledge, our findings are the first direct proof that IL-9Ra is expressed 
on follicular tonsillar B ceIls. 
Studies performed to date in mice appear to indicate that IL-9Ra expression is 
mainly found on CD5+ (B-la) as weIl as CDS- (B-lb) cells in normal mice, 169 which are 
characterized by their peritoneal and pleuropericardial location and their ability to 
respond to T-independent antigens 178. Expression ofIL-9 has been shown to promote the 
expansion of B-l cells in transgenic mice specifically B-l b CD5- lymphocytes 169. In 
humans, although the function of CD5+ B-l ce Ils is still not clear, the CDS T cell marker 
was shown in human tonsillar B cells to be expressed on follicular mantle zone B cells 
sIgD+CD38- mostly 252-254. A small proportion of CDS+ cells were found on 
CD38+/CDlO+ medium-sized B ceIls 252. Human follicular B ce Ils have been documented 
to express the highest level of CD5 amongst human B cell populations 255 •• We have 
analysed IL-9Ra. expression on human tonsillar B ceIls and shown that IL-9Ra. 
expression is specifically enriched on LD ceIls, with a high level expressed on IgD+ cells 
which are reported to express the CD5 marker, and include FM B cells (CD38-IgDl and 
founder GC cells (CD38+IgDl. This is in line with previous animal data if one is to 
compare rodent and human phenotype of cells. In the absence of human studies 
describing the expression of IL-9Ra, our results provide unique and novel data in that 
respect. Moreover, our findings delineate a potential role for IL-9 in B cell maturation. 
We have specifically identified the low density (LD) percoll-fractionated subset of 
cells which is mainly naive and antigen-activated follicular mantle zone B cells as weIl as 
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germinal center B cells (GC) 246, as the major tonsillar B cell population expressing the 
IL-9Ra chain (Figure 7a). In addition, we characterize the phenotype of LD B cells 
expressing the IL-9Ra by using three color flow cytometry and tracing two B cell 
maturation markers: IgD and CD38. Studies have shown that IgD is expressed on human 
peripheral blood memory B cells characterized by the presence of V region genes somatic 
mutation and CD27 107. This was also observed in tonsillar subpopulations whereby 
memory IgD+ B cells were identified carrying somatic mutations and expressing CD27 in 
the presence or absence of CD38 256. CD27, a member of the tumour necrosis factor-
receptor family, has been characterized as an antigen on human T cells, natural killer 
cells, plasma cells and memory B cells 257. Hence IgD+CD38- cells may be considered as 
recirculating early memory B celIs, activated B cells, or naïve B cells depending on their 
antigenic profile (CD5, CD23, CD27 expression) and the presence of genetic mutation. 
Data presented in this study show that a significant proportion of IL-9Ra positive cells 
expresses IgD (Figure 7B), the majority being on CD38+IgD+ (57%) cells and CD38-IgD+ 
(32%) cells. Moreover, IL-9Ra+ cells are found to express CD27 as well (Figure 14B), 
implicating IL-9 in the maturation of a memory subtype of tonsillar B cells. In support of 
the se data, immunohistochemistry and confocal microscopy studies demonstrate the 
colocalization of the IL-9Ra and CD 19/CD20 B cell specific markers within secondary 
lymphoid follicles, specifically on the edge ofthese follicles, coinciding with the presence 
of follicular mantle naïve and memory B cells as weIl as founder GC cells in this area 
(Figures 3, 4, 5). GC cells enter the follicles and form the dark zone through the edge of 
the follicle. In this vicinity, founder GC cells are selected and proceed to cell division 
thus forming the highly dense dark zone containing centroblasts. The recirculation of 
memory B cells to reenter the GC and undergo a second round of selection has been also 
proposed, thus widening the phenotype of B ce Ils in the FM zone of the secondary 
lymphoid organs 38. 
STATs that have been linked to IL-9 signaling include STATl, STAT3, and 
STAT5. We demonstrate that the expressed IL-9Ra chain mediates its signal mainly 
through the induction of ST A T3 and to a lesser extent STA T5 phosphorylation. Staining 
for tyrosine phosphorylated residues in STATl, STAT3, and STAT5 in tonsillar B cells 
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and LD cells demonstrates specific activation of STAT3 and not STATI in LD cells in 
the presence of IL-9 as shown by immunoblotting (Figure 9B), and flow cytometry data 
(Figure 8B). This is particularly interesting as STAT3 induce the expression of 
differentiation genes such as granzyme A, Ly-6A1E, and L-selectin 181 in IL-9 signaling 
events; whereas STAT5 phosphorylation has been linked to cellular growth and 
proliferation 183. Our data also show that STAT5 phosphorylation is upregulated 
following IL-9 stimulation of human tonsillar primary LD B cells, and this effect is 
specifically associated with IL-9Ra expression on these cells. This is the first study to 
show STAT5 upregulation in primary cells in the absence of overexpression of the 
receptor chain to augment the transduced signaIs (Figures 8, 9). However, this 
upregulation is not observed by immunoblotting, possibly due to its localization to a small 
percentage of IL-9R+ cells. Our findings are in agreement with a study undertaken on 
tonsillar B cells whereby phosphorylated STAT5 was only detected following enrichment 
of the cellular population, and the signal obtained by F ACS was weak 249. Our findings 
demonstrate the presence of a functional IL-9R on primary human GC ce Ils under normal 
physiologic conditions, in the absence of overexpression of IL-9Ra chain, as has been 
done in other studies to increase Stat activation signal and enhance its detection levels 
179,251 
Our experiments therefore point to a role for IL-9 in B cell differentiation rather 
than proliferation. A recent study implicated STAT3 in plasma cell differentiation 250. 
This may occur by binding to repressor elements in DNA and competing for these 
binding sites with Bcl-6, a transcriptional repressor of Blimp-l. Release from Bcl-6 
repression is required for differentiation into plasma cells. Since IL-9 was shown in our 
experiments to activate Stat3, IL-9 may be amplifying the synergistic effect of IL-4 which 
signaIs through Stat-6, and CD40 that activates NF-lcB on IgE transcription at the 
molecular level. Although it may be simplistic to directly attribute plasma cell 
differentiation to IL-9, it is worth contemplating the potentiai molecular players activated 
downstream of IL-9 and how they may synergize with other signaIs induced in the 
immune synapse by the different cognate molecules such as IL-4 to induce IgE 
transcription. 
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It is worth noting that the use of primary human cells in our system engendered a 
few difficulties: A higher number of human tonsillar LD B cells was needed relative to 
Jurkat cells to obtain a comparable amount of prote in to be analysed. This is one facet of 
difficulty encountered with the use of primary cells as compared to established or 
transfected cell lines. Another facet of difficulty in manipulating LD cells is due to their 
increased propensity to apoptosis. Hence, obtaining a substantially high apoptotic 
background when measuring Annexin V staining decreased the sensitivity of our system 
to detect subtle changes in apoptosis induction within differentially stimulated 
populations (± IL-9), and demonstrated the fragility of the cells used. 
Previous reports have shown that IL-9 potentiated IL-4-induced IgG, IgM and IgE 
production from normal human B lymphocytes 206,207,248. Our data demonstrate the 
expression of the IL-9Ra. mainly on IgD+ human tonsillar B cells, and further examines 
the effect of IL-9 on IgE production from LD cells in the presence of another 
inflammatory cytokine: IL-4. LD cells were cultured in the presence of a monoclonal 
antibody to CD40, and IL-4 in the presence or absence ofIL-9. We have found that IL-9 
synergizes with IL-4 to augment IgE production in low density tonsillar B cells (Figure 
10), but cou Id not induce IgE secretion on its own. This is highly interesting in the light 
of the published animal models data whereby IL-9's role in hypersensitivity and allergie 
inflammation has been documented 169,196,197. It further highlights the importance of 
considering the role ofIL-9's gene as a susceptibility factor in asthma. Evidence gathered 
thus far in humans, also points to an important role for this cytokine in allergic 
inflammation 258,259. Interestingly, the observed effects seem to be restricted or more 
pronounced in asthmatic human subjects with a predominant Th2 phenotype 175,209,211-213. 
A recent study demonstrated the coexpression of IgD and CD27 on memory B 
cells and described the presence of CD27 in superficial anatomic areas of B cell follicles 
of Iymphatic organs namely the spleen, reactive Iymph nodes, inflamed appendices, 
tonsils and terminal ilea 260. The report also shows that CD27+ B cells may also occupy 
the entire follicular periphery around the germinal centre, hence implying the presence of 
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recirculating memory B cells in addition to naïve cells in that area as the authors conclude 
260. Thus, assessing CD27 expression allows a better characterization of the phenotype of 
IL-9Ra +IgD+ cells and their maturation pathway in culture in response to stimulation with 
IL-9 and anti-CD40. 
Data presented here shows a specific upregulation for IL-9Ra and CD27 
following CD40 and IL-4 stimulation after one week of cell culture. The observed 
upregulation of the IL-9Ra and CD27 on LD B cells suggests a linkage in the role of 
these two molecules in IgE production downstream of CD40 and IL-4 stimulation. This 
evidence in primary human B cells delineates the specific stage at which IL-9 acts during 
B cell differentiation and antibody production. CD27, a member of the TNF-R family, has 
been proposed as a marker for memory B cells 104. Flow cytometric analysis revealed that 
CD27 molecules were expressed on GC Band memory B cells but not on naïve B cells 
105-109. Interestingly, upregulation of CD27 on IL-4 treated LD B cells occurs almost 
entirely on IL-9Ra positive cells. Moreover, IL-9Ra + PB MC express almost entirely 
CD27 (Figure 15) indicating their memory phenotype. This suggests the possibility of 
differentiating to an IgE secreting plasma ceIl in the presence of IL-4 with an exacerbated 
production. How does CD27 and IL-9 interact and to what extent they are complementary 
remains to be addressed. 
Our findings constitute a new paradigm showing that memory B (IL-9Ra + CD27+) 
ceIls within this subpopulation of GC B ceIls may be driving IgE production in the 
context of inflammatory responses. This is of great significance in light of the pleiotropic 
effects described for IL-9 in health and in the context of asthmatic inflammatory 
responses. 
There is no potentiation effect for IL-9 on LD B cell proliferation observed in our 
system. This is true irrespect ive of the ligand used to induce B cell proliferation (Figure 
Il). In comparison, IL-4 sustained B cell proliferation in these different conditions. In 
agreement with our results, in humans, another study reported that IL-9 was not found to 
enhance cellular proliferation of PBMCs in the presence or absence of IL-4 248. Indeed, 
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strong proliferative effects ofIL-9 have been only observed in mast cells and activated T-
cells 182. Other systems involving transfected cell lines have shown a proliferative 
response 186, however, relevance to primary cells and in vivo situations remains to be 
verified. At the molecular level, different signaling molecules, namely STATs-l,3 and 5, 
seem to be involved in the proliferative response 183. Our data show activation of STAT3 
and ST A T5 in our system. This might account for the protective anti-apoptotic effect 
observed with IL-9 in the presence of fas receptor stimulation on CD40-stimulated LD 
cells (Figure 13) which could not be attributed to a decrease in fas receptor expression 
(Figure 12). This is consistent with the published role ofSTAT5 183. Data obtained using 
transgenic mice indicate that IL-9 overexpression increases susceptibility to T -cell 
lymphoma development following irradiation or administration of low doses of mutagens 
191,194 whereas in vitro, only murine T lymphoma and myeloid leukemia cells proliferate 
in response to IL-9 and not normal cells 191,195. This evidence points to a role for IL-9 in T 
cell survival and tumor formation. Recently, a subpopulation ofthe hum an GC B cells has 
been described with an activated STAT-5 phenotype. These cells were able to self-renew 
in vitro, and differentiate to a memory B cell phenotype 273. Hence, IL-9 might play a role 
in B cell survival. 
Our findings (flow cytometry and IHC) indicate the presence of the IL-9Ra chain 
on FM B cells as well as memory B cells. However, the two populations are not distinct. 
In fact, FM B cells encompass different maturational stages of B cells: naïve, activated, 
and memory cells. The characterization of the memory B cell subset remains a challenge 
as these may be recirculating B cells that have been described as 'early memory' vs 'late 
memory'. Sorne can readily differentiate to become ASCs, or migrate to the BM where 
they can permanently reside to constitute long-term memory B cells. The coexpression of 
CD27 on IL-9Ra+ cells signifies that a proportion ofthese cells are memory B cells. How 
can we reconcile this finding with the observed flow cytometry data whereby IgD 
expression was highly found on IL-9Ra + cells. In fact, reports have shown that a fraction 
of IgD+ cells are memory B cells , thus refuting the old concept that IgD+ cells are naïve 
or immature cells. 
119 
Taken together, our data show a synergistic role for IL-9 in IgE production from 
human primary germinal center cells with IL-4 in the CD40/1 culture system. This is 
particularly relevant to in vivo situations where IL-4 and IL-9 may affect B cell 
differentiation by their presence at the immune synapse, especially in the light of genetic 
evidence linking IL-9's gene to increased susceptibility to asthma. Furthermore, our data 
shows that the observed increase in IgE is paralleled by an upregulation of IL-9Ra and 
CD27, the latter being implicated in increased IgE secretion and described previously as a 
memory B cell marker. Interestingly, CD27 is only upregulated on IL-9R positive LD B 
cells pointing to a role for IL-9 in memory B cell differentiation downstream of IL-4, 
whereby a cascade of cytokines may be involved in the production of IgE. As no strong 
proliferative response for IL-9 has been observed in our experiments, IL-9's effect seems 
to be linked to its ability to promote B cell survival as shown by its anti-apoptotic role in 
the context of fas-induced apoptosis. One may envision a role for IL-9 at a later stage of 
the immune response following IL-4. Our data show an induction ofIL-9Ra and CD27 on 
LD cells following stimulation with anti-CD40 and IL-4. The majority of the IL-9R+ cells 
coexpress CD27, these cells respond to IL-9 by an increase in IgE production. Thus, IL-9 
may play a role in the late phase of the response, with a potential synergism with other 
molecules such as CD27, supporting B cell survival and optimizing conditions for IgE 
secretion in the germinal centers. 
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CONCLUSION 
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The results presented in this study demonstrate clearly the expression of IL-9Ra 
on human LD tonsillar B ceIls, and the ability ofthis receptor to transduce signais through 
activation of STAT-3 and STAT5 transcription factors. Although IL-9 was unable to 
induce IgE secretion by itself, it potentiated IgE production trom LD cells mediated by 
IL-4. Thus, IL-9 exerts a synergistic effect with IL-4 to modulate IgE secretion. 
Our data show that the observed increase in IgE is paralleied by an upregulation of 
IL-9Ra and CD27, the latter being implicated in increased IgE secretion and described 
previously as a memory B cell marker. Our findings highlight a new role for IL-9 in 
memory B cell differentiation. 
Our results establish a new paradigm for understanding the stimulatory role of 
Th2 cytokines in the context of B-T cell interactions in the human GC, and their 
modulatory effect on B cell differentiation and IgE production. 
122 
FUTURE PERSPECTIVES 
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The specific signaIs that drive the differentiation of human naïve B cells into 
memory cells and plasma cells, have not been completely defined. Several reports 
demonstrated an involvement for cytokines in human plasma cell differentiation 102,118,261-
265. Our experiments lead to the identification of the IL-9Ra chain on FM and GC cells 
raising many interesting questions that remain to be answered. These include the precise 
mechanism by which IL-9 enhances IgE production from CD40 and IL-4 stimulated LD 
B cells, and whether CD27 synergizes with IL-9 in that respect. Therefore, it will be of a 
great interest to identify the molecular components induced by IL-9 such as possibly Akt, 
Bel-2 or Bel-xl to enhance survival of B cells. Determining the expression of B cell 
transcription factors activated by IL-9 such as BLIMP-l, which is required for plasma cell 
differentiation 266, AID with its role in CSR 267, and Bel-6, which is involved in GC 
reactions 268 would elucidate the precise contribution ofIL-9 to IgE production. 
On the other hand, to examine the role of CD27, CD27+ cells could be purified 
and their IgE production assessed in the presence or absence of IL-9 with CD70 
transfectants. A dose increase of IL-9 would allow a dose-dependent effect to be 
observed. Neutralization of CD70-CD27 interaction by the use of anti-CD70 MAb would 
confirm the role ofCD27. CD40 antibodies may be added to check ifIgE secretion can be 
induced in the presence or absence of CD40 stimulation. Next, studying this interaction in 
asthmatic subjects would prove helpful in confirming IL-9's role in vivo in memory B 
cell differentiation. 
Interestingly, we have identified the expression of the IL-9Ra on human tonsillar 
dendritic cells by immunohistochemistry. Double expression of DC-LAMP, a member of 
the LAMP family of associated glycoproteins, and IL-9Ra was demonstrated by confocal 
microscopy using a Mab to DC-LAMP which is specifically expressed by mature 
interdigitating DC (lDC) 84, on human tonsillar sections (Figure 1). These cells (lDC) are 
mature DC located in T cell areas of Iymphoid tissues 269,270. The implications of this 
expression merits further investigation especially in light of the role of DC in driving 
Th 1-Th2 differentiation. 
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Ultimately, the researcher's objective is to bridge bench to clinic. IL-9's role in 
allergie inflammation and asthma has been documented with pleiotropic effects on the 
differentiation of major key players of the asthmatic immune response namely mast cells 
and eosinophils. An immunotherapeutic approach targeting this cytokine may help 
alleviate the exacerbated responses observed. 
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Figure 1: Expression ofIL-9Ralpha on IDe of human tonsils. Tonsillar tissue sections 
were prepared and stained as described in materials and methods. A primary monoclonal 
antibody directed against DC LAMP was labeled with Alexa Fluor 568 using the Zenon 
Red kit from Molecular Probes. Monoclonal Ab against IL-9Ra. was followed by an 
FITC-conjugated goat anti-mouse IgG Ab. Double positive cells show merged red and 
green colors (yellow). Single positive areason cells are also discernable. 
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IL-9 Upregulates IgE Production in IL-4 Stimulated Human Follicular Germinal 
Center B Cells. 
Lama M Fawaz l , Oumnia Hajoui2, Bruce D Mazerl ,2 
IDivision of Experimental Medicine, Meakins-Christie Laboratories, McGill University, Montreal; 
2Division of Allergy and Immunology, Montreal Children's Hospital Research Institute and Meakins-
Christie Laboratories, McGill University, Montreal, QC, Canada. 
Rationale: IL-9 is a pleiotropic cytokine secreted by activated Th2 cells. 
Interleukin-9 and the a-chain of the IL-9 receptor (IL-9Ra) have been shown to affect the 
differentiation pathway of different cell types including human T ceIls, eosinophils, and 
mast cells. In vivo and in vitro studies have linked IL-9 to increased immunoglobulin 
production, specifically IgE. We have recently characterized the expression of the IL-9R 
on human tonsillar B cells at different stages of their maturation. Our findings show for 
the first time that a functional IL-9Ra chain is expressed preferentially on human 
follicular germinal center B ceIls, suggesting a potential role for IL-9 in B cell 
differentiation and IgE production. Methods: In order to assess directly the effect of IL-9 
on IgE production from human B cells. Freshly purified human tonsillar B cells were 
fractionated, using a discontinuous percoll density gradient, into three populations 
representing different stages of B lymphocyte maturation: low density (LD), medium 
density (MD), and high density (HD) cells. LD ceIls, which are germinal center cells 
expressing the highest level of IL-9Ra, were stimulated with CD40L and IL-9 in the 
presence or absence of IL-4 and IgE production was measured by ELISA. Results: 
Although IL-9 was unable to induce IgE secretion by itself, it potentiated IgE production 
mediated by IL-4. Thus, IL-9 exerts a synergistic effect with IL-4 to modulate IgE 
production. This is of great interest in the light ofthe linkage ofIL-9 and the IL-9R genes 
to increased susceptibility to allergy and asthma. Further characterization of the 
phenotypic changes resulting from IL-9 stimulation leading to the upregulation of IgE 
production are underway. 
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Demonstration of Interleukin-9 Receptor Function in Human Germinal Center B 
Cells 
L. M. Fawaz l , X. Lil, Q. A. Hamid2, B. Mazer! 
lAllergy and Immunology, Montreal Children Hospital Research Institute and Meakins Christie 
Laboratories, Montreal, PQ, CANADA, 2Department ofPathology, Meakins Christie Laboratories, McGill 
University, Montreal, PQ, CANADA. 
Rationale: IL-9 is a pleiotropic cytokine secreted by activated Th2 cens, which 
has been linked to bronchial hyper-responsiveness and asthma. We have shown that 
human tonsillar B cells express IL-9R predominantly in the germinal center (GC). 
Methods: To as certain the functionality of the IL-9R expressed on Ge B cens, we 
activated low density (LD) B cens with IL-9 for 15 min, and assessed their prote in 
phosphorylation status. Human tonsillar B cens were fractionated into low, medium and 
high density fractions, using discontinuous percoll density gradients. The low density 
fraction includes sIgD- Ge B cells. Results: Immunoblotting demonstrated an increase in 
total phosphotyrosine levels in LD cens stimulated with IL-9 compared to non stimulated 
cens or IL-9 treated total B cens. Because ST AT -5 (Signal transducer and activator of 
transcription 5) belongs to the family of transcription factors which mediate the cellular 
response to a variety of cytokines including IL-9, we sought to determine STAT-5 
phosphorylation status following IL-9 stimulation of Ge cens. Using a phosphospecific 
antibody that detects the phosphorylated tyrosine residue associated with activated STAT-
5 (Tyr 694), we analyzed expression ofphosphorylated STAT-5 by flow cytometry. The 
results show an upregulation of ST AT -5 phosphorylation following IL-9 stimulation 
specificany in LD cens and not in total B cells, MD or HD cells. Conclusions: These 
results demonstrate for the first time the expression of a functional IL-9R on Ge B cens. 
Further studies will be done to define the activation status of other described IL-9 induced 
STATs namely STAT-l and 3. 
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Expression of Interleukin-9 Receptor Alpha on Germinal Center B Cells: Potential 
Role for Interleukin-9 in B Cell Maturation 
Lama Fawaz·, Abdelilah Soussi-Gounnl, Qutayba A Hamid, Bruce D Mazer· 
*Meakins-Christie Laboratory, McGiII University, Montreal, QC, Canada §McGiII University, Montreal, 
QC, Canada. 
IL-9 is a pleiotropic cytokine secreted by activated Th2 cells. Recently, the human 
IL-9 receptor (lL-9R) gene locus and IL-9 have been linked to bronchial 
hyperresponsiveness and asthma. In vitro studies have pointed to a role for IL-9 in 
enhancing the release of IgE from B cells. Although IL-9 may play a role in B cell 
differentiation, the direct effect of IL-9 on B cell survival and differentiation has not been 
addressed. Furthermore, the expression of the IL-9R on B cells at different stages of their 
development has not been characterized. We therefore determined the expression of IL-
9R using human tonsillar B cells. Human tonsillar B cells were fractionated, using a 
discontinuous percoll density gradient, into three populations representing different stages 
of B lymphocyte maturation: low density (recovered in the 30-50% Percoll fraction), 
which represents sIgD- germinal center B cells, medium density (50-60%), which are 
primarily centroblasts and centrocytes, and high density (> 60%) or more mature B cells. 
We have determined the expression ofthe IL-9Ra chain by immunocytochemistry, FACS 
analysis and immunohistochemistry. Immunocytochemistry was performed on freshly 
isolated purified human tonsillar B cells using a monoclonal antibody to the alpha chain 
of the IL-9R. This clearly demonstrated the presence of the IL-9Ra protein on tonsillar B 
cells. Using F ACS analysis, unfractionated as weil as fractionated B cells showed 
expression of IL-9Ra. However, IL-9Ra expression was predominantly higher in the low 
density or germinal center fraction of the B ce Ils (38.7%), as compared to the medium 
density (21.78%), and high density fractions (16.22%). These findings prompted us to 
further investigate the precise localization of the IL-9Ra positive B cells within the 
germinal centers. For this purpose, immunohistochemistry was performed on sections of 
human tonsils. Using double staining with anti-IL-9Ra and anti-CD20, we found that 
CD20+ B cells within the secondary lymphoid follicles, as weil as cells on the edge of 
these follicles displayed IL-9Ra. Analysis of CD38 and IgD expression on IL-9Ra 
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positive cells by three color flow cytometry revealed that IL-9Ra was expressed on naive 
follicular mantle zone B cells (CD38-IgD+) and germinal center cells (CD38+IgD+). 
Taken together, these results confirm that IL-9Rca is principally expressed on naive B 
lymphocytes and early germinal center cells. These data show for the first time that the 
IL-9Ra chain is expressed on human follicular germinal center B cells, and suggest a 
potential role for IL-9 in B cell differentiation. Further studies will be done to define the 
effect of IL-9 on follicular B cells.We hypothesize that IL-9 is an early signal that cou Id 
promote isotype switching and consequently affect IgE production. 
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A Comparative Study of the Effects of Intact and Fragmented Intravenous 
Immunoglobulin (IVIG) on In Vitro IgE Production by Human B Lymphocytes 
Q Zhuang, R Millette. L Fawaz. B Mazer 
Division of Allergy and Immunology, Montreal Children's Hospital, Meakins-Christie Laboratol)', McGill 
University, Montreal, Canada. 
Background: Intravenous immunoglobulin (IVIG) has been employed extensively 
in the treatment of auto immune and allergic disorders, which may be mediated by the 
overproduction of pathogenic antibodies. Numerous mechanisms have been proposed to 
explain its beneficial actions, yet none satisfactorily explain aIl clinical situations. We 
have previously demonstrated that IVIG inhibits IgE production in highly purified hum an 
tonsillar B cells stimulated with IL-4 and anti-CD40 antibody (anti-CD40). Objectives: 
To further clarify the mechanism underlying the inhibition of cell proliferation and IgE 
synthesis by IVIG, we have investigated the effects of intact whole molecule IVIG as 
weIl as the F(ab')2 and Fc fragments ofIVIG. Methods: Ruman tonsillar B-Iymphocytes 
were purified by Ficoll-Hypaque density centrifugation and T cells were removed by E-
rosetting. Cell proliferation was measured by [3H] thymidine incorporation and 
supernatant IgE was determined by ELISA. Cell phenotyping and cell cycle analysis was 
performed by flow cytometry. Fractionated IVIG was kindly provided by Centeon Corp. 
Results: Whole molecular IVIG inhibited anti-CD40IIL-4 stimulated IgE production in a 
dose-dependent manner (I-20mg/ml). Similarly the Fc fragment also blocked the 
production of IgE in stimulated tonsillar B cells at equimolar doses ranging from 0.4-
8mg/ml. The F(ab')2 portion significantly decreased the IgE production in anti-CD40lIL4 
stimulated B lymphocytes (dose range 0.6-12 mglml); however, this fragment increased 
the baseline IgE level in the supematant of unstimulated B lymphocytes. Similar to intact 
IVIG, the inhibition oflgE production by fragmented IVIG was associated with inhibition 
ofB cell proliferation, as both the F(ab')2 and Fc fragments significantly decreased [3H]-
thymidine incorporation into B cells. The F(ab')2 fragment was more potent than the Fc 
fragment at the above equal molar concentrations. The inhibitory effects of aIl IVIG 
preparations were not due to the induction of apoptosis as neither the intact nor the 
fragmented IVIG had any significant effect on cell cycle or programmed cell death at the 
concentrations used. Conclusion: These data show that both F(ab')2, and Fc portions 
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contribute to the effect of IVIG, indicating multiple mechanisms of IVIG 
immunomodulatory activity. 
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Expression ofIL13 Receptor Alpha 1 in Human B Cells Committed to Produce IgE 
H. Zheng\ O. Hajouil, L. M. Fawaz\ B. D. Mazerl ,2. 
lMeakins Christie Laboratories, McGill University, Montreal, PQ, CANADA, 2Montreal Chilclren's 
Hospital, Montreal, PQ, CANADA. 
Rationale: Our previous studies have shown that human B lymphocytes, stimulated to 
synthesize IgE, produce IL-l3 as an autocrine growth factor. Little is known about the 
expression ofIL-l3 receptor alpha 1 (IL-l3Ral) during the development ofIgE secreting 
B cells. Methods: Purified B cells were isolated from human tonsils and cultured with or 
without anti-CD40 antibody (anti-CD40, 1 Ilg/ml), recombinant human IL4 (400 Iml), 
ILl3 neutralizing antibody (3 Ilg/ml). Cells were serially harvested during 14 day culture. 
IL-l3Ra mRNA expression was evaluated by real time-PCR, and IL-l3Ral, IL-4Ra; and 
CD23 surface expression was examined by flow cytometry and laser scanning 
microscopy.Results: IL l3Ra 1 rnRNA was expressed at very low levels prior to 
stimulation, but increased following addition of anti-CD40. Over a 14 day culture period, 
surface ILl3Ral was detected at low levels (MFI 65.4 ± 29.8) in unstimulated B cells, 
but increased significantly at l, 5, 10, and 14 days after anti-CD401IL4 stimulation (MFI 
249.6 ± 56.5 at day 10), P<O.OI for all time points). In contrast, IL4Ra was highly 
expressed in unstimulated B cells, and did not significantly increase after stimulation. 
CD23 expression increased following CD401IL4 stimulation (P<0.01) and was co-
expressed on cells that expressed IL-l3Rai. Anti-ILl3 treatment had no effect on either 
ILl3Ral or CD23 expression following stimulation. Conclusions: ILl3Ral and IL4Ra 
are not equally expressed in resting B lymphocytes. ILl3Ral and CD23 are highly 
inducible following B cell activation. These data for the frrst time demonstrate the 
kinetics ofIL-l3Ral expression on human B cells. 
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B-Lymphocyte-Derived IL-4 Contributes to Th2 Differentiation of T Lymphocytes 
Oumnia Hajoui, Lama Fawaz, Ramesh Janani, Roxane Millette, Bruce D Mazer 
Meakins-Christie Laboratory, McGill University, Montreal, QC, Canada 
Background: IL-4 is the crucial cytokine that causes T helper lymphocytes to 
differentiate into Th2 cells. The cells that supply IL-4 for Th2 differentiation are not weil 
defined. Data from several laboratories, as weil as work that has been recently performed 
in our laboratory suggests that B cells can be a source of IL-4. Platelet-activating factor 
(PAF), a potent lipid mediator released during inflammatory and immune responses, has a 
wide range of physiologic actions. Previous work in our laboratory has detected 
functional PAF receptors on human tonsillar B cells, which upon stimulation with PAF 
induce the B lymphocytes to produce IL-4. PAF induced IL-4 mRNA expression is 
present on approximately 17% of CD20+ cells in tonsils, and IL-4 was detected in 
supernatants of tonsillar B cell cultures after 48-72 h. We wished to determine if B cell 
derived IL-4 was capable of directing Th2 differentiation. Methods: B cells were 
stimulated by PAF (107 M) and cultured with mixed tonsillar T lymphocytes. The T 
lymphocytes were either unstimulated or cultured with anti-CD3 and anti-CD28 
antibodies for 2 days before exposure to B cells. After 5 days of coculture, detection of 
intracellular interferon-y (INF-y) and IL-4 was assessed by flow cytometry gating on 
CD4+ T lymphocytes. Results: The tonsils used in these experiments were obtained from 
random pediatric patients, and were subject to sorne variability. We observed 2 patterns 
of cytokine production by CD4+ T lymphocytes stimulated with anti-CD3/CD28 
antibodies for 5 days. A number of specimens produced INF-y with little IL-4, and an 
equal number produced primarily IL-4. In tonsils where the CD4+ population was 
predisposed to INF-y production, coculture of PAF-stimulated B-cells with T 
lymphocytes for 5 days lead to abrogation ofINF-y synthesis (Control: 61% vs 11% IFN-
Y secreting cells in T:B co-culture), suggesting that PAF-stimulated B cells inhibited INF-
y production by the T cells. In tonsils where the CD4+ population was predisposed to IL-
4 production upon stimulation with anti-CD3/CD28 antibodies, co-culture of PAF-
stimulated B with T lymphocytes increased the production ofIL-4 (19.3% increase in IL-
4 secreting cells after 5 days of co-culture compared to 9% in the control). Conclusion: 
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These preliminary results suggest that IL-4 from human B cells may regulate the 
differentiation of ThO cells. PAF stimulated B celIs, because of their ability to produce 
IL-4, can provide both a negative and positive signal for Thl and Th2 cells. 
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